CA3026564A1 - Proteasome inhibitors - Google Patents
Proteasome inhibitors Download PDFInfo
- Publication number
- CA3026564A1 CA3026564A1 CA3026564A CA3026564A CA3026564A1 CA 3026564 A1 CA3026564 A1 CA 3026564A1 CA 3026564 A CA3026564 A CA 3026564A CA 3026564 A CA3026564 A CA 3026564A CA 3026564 A1 CA3026564 A1 CA 3026564A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- proteasome
- compound
- activity
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079156 Proteasome inhibitor Drugs 0.000 title claims description 23
- 239000003207 proteasome inhibitor Substances 0.000 title claims description 23
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims abstract description 101
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims abstract description 101
- 150000001875 compounds Chemical class 0.000 claims abstract description 85
- -1 methoxy, ethyl Chemical group 0.000 claims abstract description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 22
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 18
- 239000012039 electrophile Substances 0.000 claims abstract description 17
- 230000027455 binding Effects 0.000 claims abstract description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- 230000002708 enhancing effect Effects 0.000 claims abstract description 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 150000002367 halogens Chemical class 0.000 claims abstract description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims abstract description 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000000816 peptidomimetic Substances 0.000 claims description 9
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 7
- 241000024188 Andala Species 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 150000002611 lead compounds Chemical class 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 230000001810 trypsinlike Effects 0.000 claims description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 3
- 125000000962 organic group Chemical group 0.000 claims description 3
- 229960002317 succinimide Drugs 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- UCNNZELZXFXXJQ-BZSNNMDCSA-N Leu-Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCNNZELZXFXXJQ-BZSNNMDCSA-N 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 108010017893 alanyl-alanyl-alanine Proteins 0.000 claims description 2
- 230000036953 caspase-like activity Effects 0.000 claims description 2
- 230000037012 chymotrypsin-like activity Effects 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 description 59
- 230000015572 biosynthetic process Effects 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 40
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- 230000005764 inhibitory process Effects 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
- 230000003197 catalytic effect Effects 0.000 description 19
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 230000008685 targeting Effects 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 239000013078 crystal Substances 0.000 description 16
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical group C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- IUDBVFIQSSOIDB-TWOQFEAHSA-N n-[(2s)-3-hydroxy-1-[[(2s)-1-[(2r)-2-(hydroxymethyl)oxiran-2-yl]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-6-methylheptanamide Chemical compound CC(C)CCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(CO)CO1 IUDBVFIQSSOIDB-TWOQFEAHSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 150000001721 carbon Chemical group 0.000 description 13
- 150000002576 ketones Chemical class 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 229940093499 ethyl acetate Drugs 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 210000004988 splenocyte Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108010064641 ONX 0912 Proteins 0.000 description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 10
- 239000004473 Threonine Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 238000010511 deprotection reaction Methods 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 10
- 229950005750 oprozomib Drugs 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 9
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N epoxomicin Chemical compound CC[C@H](C)[C@H](N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 DOGIDQKFVLKMLQ-JTHVHQAWSA-N 0.000 description 9
- 108700002672 epoxomicin Proteins 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 230000002427 irreversible effect Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 230000000269 nucleophilic effect Effects 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 7
- 238000000423 cell based assay Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 150000002924 oxiranes Chemical class 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 6
- 229960001467 bortezomib Drugs 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 6
- 108010021331 carfilzomib Proteins 0.000 description 6
- 229960002438 carfilzomib Drugs 0.000 description 6
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 125000000468 ketone group Chemical group 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 125000004452 carbocyclyl group Chemical group 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 238000005897 peptide coupling reaction Methods 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WQAVPPWWLLVGFK-VTNASVEKSA-N (2s)-3-(4-methoxyphenyl)-n-[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]-2-[[(2s)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1=CC(OC)=CC=C1C[C@@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)NC(=O)[C@H](C)NC(=O)CN1CCOCC1 WQAVPPWWLLVGFK-VTNASVEKSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108010079844 PR-957 Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012830 cancer therapeutic Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007771 core particle Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- UVFAEQZFLBGVRM-MSMWPWNWSA-N succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CCC(O)=O)CC(C)C)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C1=CC=C(O)C=C1 UVFAEQZFLBGVRM-MSMWPWNWSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 2
- NJQGIDVCNBZXLG-LURJTMIESA-N (2s)-3-hydroxy-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound OC[C@@H](C(O)=O)N(C)C(=O)OC(C)(C)C NJQGIDVCNBZXLG-LURJTMIESA-N 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- QCXCIYPOMMIBHO-UHFFFAOYSA-N 2-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)S1 QCXCIYPOMMIBHO-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ZPLVYYNMRMBNGE-UHFFFAOYSA-N Eponemycin Natural products CC(C)CCCCC(=O)NC(CO)C(=O)NC(CC(C)=C)C(=O)C1(CO)CO1 ZPLVYYNMRMBNGE-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 2
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 150000004718 beta keto acids Chemical class 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 125000005620 boronic acid group Chemical group 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- ZPLVYYNMRMBNGE-TWOQFEAHSA-N eponemycin Chemical compound CC(C)CCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)=C)C(=O)[C@@]1(CO)CO1 ZPLVYYNMRMBNGE-TWOQFEAHSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- LQTMEOSBXTVYRM-VIFPVBQESA-N tert-butyl n-[(2s)-1-hydroxy-4-methylpentan-2-yl]carbamate Chemical compound CC(C)C[C@@H](CO)NC(=O)OC(C)(C)C LQTMEOSBXTVYRM-VIFPVBQESA-N 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ZURHEVZANDWETP-BYPYZUCNSA-N (2s)-2-(1h-pyrazol-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=1C=NNC=1 ZURHEVZANDWETP-BYPYZUCNSA-N 0.000 description 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 description 1
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 description 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 description 1
- WRQSUCJAKAMYMQ-YFKPBYRVSA-N (2s)-2-(thiophen-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=1C=CSC=1 WRQSUCJAKAMYMQ-YFKPBYRVSA-N 0.000 description 1
- TWBYJJWSNXDRCJ-RXMQYKEDSA-N (3R)-3-ethenyl-1,3-dihydropyrrol-2-one Chemical compound C=C[C@@H]1C=CNC1=O TWBYJJWSNXDRCJ-RXMQYKEDSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- VFFFESPCCPXZOQ-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol;oxirane Chemical compound C1CO1.OCC(CO)(CO)CO VFFFESPCCPXZOQ-UHFFFAOYSA-N 0.000 description 1
- ZCHGODLGROULLT-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol;propane-1,2-diol Chemical compound CC(O)CO.OCC(CO)(CO)CO ZCHGODLGROULLT-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- BXRLWGXPSRYJDZ-VKHMYHEASA-N 3-cyano-L-alanine Chemical compound OC(=O)[C@@H](N)CC#N BXRLWGXPSRYJDZ-VKHMYHEASA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- YBZBSZXGHPEUBL-UHFFFAOYSA-N C(C)(=O)NS(=O)=O.C1=CC=CC=C1 Chemical compound C(C)(=O)NS(=O)=O.C1=CC=CC=C1 YBZBSZXGHPEUBL-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- BJSKBZUMYQBSOQ-UHFFFAOYSA-N Jeffamine M-600 Chemical compound COCCOCC(C)OCC(C)OCC(C)OCC(C)OCC(C)OCC(C)OCC(C)OCC(C)OCC(C)N BJSKBZUMYQBSOQ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- ZIAXNZCTODBCKW-UHFFFAOYSA-N TMC-95 C Natural products C12=CC=CC3=C2NC(=O)C3(O)C(O)C(C(=O)NC=CC)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(=O)C(C)CC)CC2=CC=C(O)C1=C2 ZIAXNZCTODBCKW-UHFFFAOYSA-N 0.000 description 1
- ZIAXNZCTODBCKW-BOYGTWLISA-N TMC-95A Chemical compound O[C@@H]([C@]1(O)C(=O)NC2=C1C=CC=C21)[C@@H](C(=O)N\C=C/C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)C(=O)[C@@H](C)CC)CC2=CC=C(O)C1=C2 ZIAXNZCTODBCKW-BOYGTWLISA-N 0.000 description 1
- 108010065317 TMC-95A Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- ITFCTBFBEKRKDC-UHFFFAOYSA-N [O].OC Chemical compound [O].OC ITFCTBFBEKRKDC-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920003174 cellulose-based polymer Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 1
- 229950001466 delanzomib Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 1
- 229960003648 ixazomib Drugs 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 150000002613 leucine derivatives Chemical class 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QDMZCBABQCORRW-BYPYZUCNSA-N methyl (2s)-2-amino-4-hydroxybutanoate Chemical compound COC(=O)[C@@H](N)CCO QDMZCBABQCORRW-BYPYZUCNSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229940078547 methylserine Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical class OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229930182852 proteinogenic amino acid Natural products 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000005055 short column chromatography Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005323 thioketone group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
- C07K5/06069—Ser-amino acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a compound of formula (I), wherein X is C=0, C=S or B-OH; Y is an electrophile and Z is a leaving group, or Y--Z is an electrophile; R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery; or (b) a group binding between subunits ß1 and ß2 of a proteasome; R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
Description
Proteasome inhibitors The present invention relates to a compound of formula (I) Ri X 1( Z
(I), wherein X is C=0, C=S or B-OH;
Y is an electrophile and Z is a leaving group, or Y¨Z is an electrophile;
R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery;
or (b) a group binding between subunits (31 and p2 of a proteasome;
R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
In this specification, a number of documents including patent applications and manufacturer's manuals are cited. The disclosure of these documents, while not considered relevant for the patentability of this invention, is herewith incorporated by reference in its entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
In recent years, the proteasome has been validated as a therapeutic target for anti-cancer therapy and the first proteasome inhibitor Bortezomib has been approved in 2008 for the treatment of multiple myeloma and mantle cell lymphoma. Current efforts focus on the development of second generation inhibitors with improved pharmacological properties.
(I), wherein X is C=0, C=S or B-OH;
Y is an electrophile and Z is a leaving group, or Y¨Z is an electrophile;
R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery;
or (b) a group binding between subunits (31 and p2 of a proteasome;
R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
In this specification, a number of documents including patent applications and manufacturer's manuals are cited. The disclosure of these documents, while not considered relevant for the patentability of this invention, is herewith incorporated by reference in its entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
In recent years, the proteasome has been validated as a therapeutic target for anti-cancer therapy and the first proteasome inhibitor Bortezomib has been approved in 2008 for the treatment of multiple myeloma and mantle cell lymphoma. Current efforts focus on the development of second generation inhibitors with improved pharmacological properties.
2 Epoxyketone inhibitors of the proteasome are desirable cancer therapeutics.
The dose required to elicit inhibition is considerably lower than the boronic acid proteasome inhibitor Bortezomib. Additionally, many patients treated with Bortezomib acquire resistance to this agent through mutations in the 13-subunits, i.e. the active site subunits of the proteasome. It has been recognized in recent years that Bortezomib resistant patients are responsive to Carfilzomib, which is the only epoxyketone inhibitor approved for clinical use today. This further highlights the importance of the development of additional epoxyketone inhibitors and/or inhibitors exhibiting similar inhibition properties as epoxyketone inhibitors. In pursuit of this goal most approaches today focus on the modification of the peptide backbone of epoxyketone inhibitors. These modifications include the introduction of natural and non-natural amino acids to increase the specificity for a given proteasome active site, the solubility of epoxyketone inhibitors, the bioavailability and the possibility to orally administer cancer therapeutics. In addition, medicinal chemistry approaches have focused on the addition of capping agents at the S4 position, which increase the absorptive properties of epoxyketone inhibitors and/or protect them from the harshly acidic environment of the gastro-intestinal tract.
The parent molecule of this class epoxyketone proteasome inhibitors, epoxomicin, was first isolated as a natural product synthesized by an Actinomyces bacterial strain.
Later, another molecule of this class was found, viz. eponemycin, and several synthetic variants of these molecules (Figure 1) are presently in clinical trials as cancer therapeutics (Bennett and Kirk, Curr. Opin. Drug Discov. Devel., 11, 616-625 (2008); Demo et al., Cancer Res., 67, 6383-6391 (2007)).
The efficacy of epoxyketone inhibitors, is a consequence of the dual electrophile nature of the epoxyketone group. Based on several co-crystal structures of epoxyketone inhibitors with yeast, mouse and human 20S proteasomes, it has been described that the y-hydroxyl group of the proteasome active site catalytic threonine reacts with the ketone moiety, whereas the N-terminal amino group of Thrl reacts with the carbon atom of the epoxide of the inhibitor, which is in a-position to the ketone, in an irreversible manner. As shown in Scheme 1, this suggested chemistry results in the formation of an 1,4-morpholine ring product, which is formed by the active site catalytic threonine and the epoxyketone inhibitor (Groll et al., Journal of the American Chemical Society, 122, 1237-1238 (2000)).
The dose required to elicit inhibition is considerably lower than the boronic acid proteasome inhibitor Bortezomib. Additionally, many patients treated with Bortezomib acquire resistance to this agent through mutations in the 13-subunits, i.e. the active site subunits of the proteasome. It has been recognized in recent years that Bortezomib resistant patients are responsive to Carfilzomib, which is the only epoxyketone inhibitor approved for clinical use today. This further highlights the importance of the development of additional epoxyketone inhibitors and/or inhibitors exhibiting similar inhibition properties as epoxyketone inhibitors. In pursuit of this goal most approaches today focus on the modification of the peptide backbone of epoxyketone inhibitors. These modifications include the introduction of natural and non-natural amino acids to increase the specificity for a given proteasome active site, the solubility of epoxyketone inhibitors, the bioavailability and the possibility to orally administer cancer therapeutics. In addition, medicinal chemistry approaches have focused on the addition of capping agents at the S4 position, which increase the absorptive properties of epoxyketone inhibitors and/or protect them from the harshly acidic environment of the gastro-intestinal tract.
The parent molecule of this class epoxyketone proteasome inhibitors, epoxomicin, was first isolated as a natural product synthesized by an Actinomyces bacterial strain.
Later, another molecule of this class was found, viz. eponemycin, and several synthetic variants of these molecules (Figure 1) are presently in clinical trials as cancer therapeutics (Bennett and Kirk, Curr. Opin. Drug Discov. Devel., 11, 616-625 (2008); Demo et al., Cancer Res., 67, 6383-6391 (2007)).
The efficacy of epoxyketone inhibitors, is a consequence of the dual electrophile nature of the epoxyketone group. Based on several co-crystal structures of epoxyketone inhibitors with yeast, mouse and human 20S proteasomes, it has been described that the y-hydroxyl group of the proteasome active site catalytic threonine reacts with the ketone moiety, whereas the N-terminal amino group of Thrl reacts with the carbon atom of the epoxide of the inhibitor, which is in a-position to the ketone, in an irreversible manner. As shown in Scheme 1, this suggested chemistry results in the formation of an 1,4-morpholine ring product, which is formed by the active site catalytic threonine and the epoxyketone inhibitor (Groll et al., Journal of the American Chemical Society, 122, 1237-1238 (2000)).
3 Lyses3, = NH2 0, HO 4,0 =a, HO
Thr Thr2 14, 1 oil,' "== 5 3 40. N %2 === -6412 4 Thr2 CAT
Scheme 1: Proposed chemical reaction mechanism for the inhibition of proteasome active sites by epoxy ketone inhibitors (Groll et al., /oc. cit.) Initially, the y-hydroxyl group of the actives site catalytic threonine amino acid side chain esterifies the ketone group of the epoxyketone inhibitor by a nucleophilic attack (left). The nucleophilic addition reaction results in the formation of a hemiketal intermediate where the y-hydroxyl group of the active site catalytic threonine is reversibly bound to the epoxyketone inhibitor (middle).
The N-terminal amino group of the active site catalytic threonine then reacts with the electrophilic carbon atom in a-position to the ketone to form the covalently modified proteasome active site (right). This 1,4-morpholine ring structure which is formed by both the proteasome active site and the inhibitor results in an irreversible inhibition of the proteasome active site.
This proposed inhibition scheme was formulated based on crystal structures where the electron density in the 20S proteasome active site was of insufficient resolution and quality to unequivocally model the inhibited state in atomic detail. Yet, the common belief that irreversible proteasome inhibition by epoxyketones yields a six atom ring adduct is well-established in the art; see, for example, the section dedicated to Carfilzomib and references cited therein in the review about proteasome inhibitors by Kubiczkova et al.
(J. Cell. Mol.
Med., 18, 947-961 (2014)).
There remains a significant need to develop new proteasome inhibitors, in particular improved proteasome inhibitors, improvements including activity at lower dosage and less side effects.
This technical problem has been solved by the subject-matter of the enclosed claims.
Thr Thr2 14, 1 oil,' "== 5 3 40. N %2 === -6412 4 Thr2 CAT
Scheme 1: Proposed chemical reaction mechanism for the inhibition of proteasome active sites by epoxy ketone inhibitors (Groll et al., /oc. cit.) Initially, the y-hydroxyl group of the actives site catalytic threonine amino acid side chain esterifies the ketone group of the epoxyketone inhibitor by a nucleophilic attack (left). The nucleophilic addition reaction results in the formation of a hemiketal intermediate where the y-hydroxyl group of the active site catalytic threonine is reversibly bound to the epoxyketone inhibitor (middle).
The N-terminal amino group of the active site catalytic threonine then reacts with the electrophilic carbon atom in a-position to the ketone to form the covalently modified proteasome active site (right). This 1,4-morpholine ring structure which is formed by both the proteasome active site and the inhibitor results in an irreversible inhibition of the proteasome active site.
This proposed inhibition scheme was formulated based on crystal structures where the electron density in the 20S proteasome active site was of insufficient resolution and quality to unequivocally model the inhibited state in atomic detail. Yet, the common belief that irreversible proteasome inhibition by epoxyketones yields a six atom ring adduct is well-established in the art; see, for example, the section dedicated to Carfilzomib and references cited therein in the review about proteasome inhibitors by Kubiczkova et al.
(J. Cell. Mol.
Med., 18, 947-961 (2014)).
There remains a significant need to develop new proteasome inhibitors, in particular improved proteasome inhibitors, improvements including activity at lower dosage and less side effects.
This technical problem has been solved by the subject-matter of the enclosed claims.
4 PCT/EP2017/063699 Accordingly, the present invention, in a first aspect relates to a compound of formula (I) Y.
Ri X Z
(I), wherein X is C=0, C=S or B-OH;
Y is an electrophile and Z is a leaving group, or Y¨Z is an electrophile;
R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery;
or (b) a group binding between subunits 131 and 132 of a proteasome;
R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
It is understood that throughout the present specification the term "compound"
encompasses pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, codrugs, cocrystals, tautomers, racemates, enantiomers, or diastereomers or mixtures thereof unless mentioned otherwise.
The compounds of formula (I) have a bipartite structure. R1, herein also referred to as "targeting group", is responsible for targeting the compound of formula (I) to the proteolytic site of the proteasome. This part of the compound may build on established knowledge; for details see below. The remainder of said compound is displayed in more detail in formula (I).
This part is also referred to as "headgroup" or "warhead" herein. It is responsible for the irreversible inhibition of the proteasome. The headgroup requires an electrophile (Y or Y¨Z) in 13-position relative to the functional group X. Such a design is contrary to the common belief that irreversible inhibition of the proteolytic site of the proteasome yields a morpholine ring. To explain further, as can be seen in Scheme 1 displayed herein above, the expected mechanism involves a nucleophilic attack of the amino group of Thr1 on a position which is in
Ri X Z
(I), wherein X is C=0, C=S or B-OH;
Y is an electrophile and Z is a leaving group, or Y¨Z is an electrophile;
R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery;
or (b) a group binding between subunits 131 and 132 of a proteasome;
R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
It is understood that throughout the present specification the term "compound"
encompasses pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, codrugs, cocrystals, tautomers, racemates, enantiomers, or diastereomers or mixtures thereof unless mentioned otherwise.
The compounds of formula (I) have a bipartite structure. R1, herein also referred to as "targeting group", is responsible for targeting the compound of formula (I) to the proteolytic site of the proteasome. This part of the compound may build on established knowledge; for details see below. The remainder of said compound is displayed in more detail in formula (I).
This part is also referred to as "headgroup" or "warhead" herein. It is responsible for the irreversible inhibition of the proteasome. The headgroup requires an electrophile (Y or Y¨Z) in 13-position relative to the functional group X. Such a design is contrary to the common belief that irreversible inhibition of the proteolytic site of the proteasome yields a morpholine ring. To explain further, as can be seen in Scheme 1 displayed herein above, the expected mechanism involves a nucleophilic attack of the amino group of Thr1 on a position which is in
5 , a to the ketone of the epoxyketone inhibitor. The epoxy group is amenable to such , nucleophilic attack, noting that the carbon in a-position to the ketone is electrophile.
, , ' The present inventors determined more than 20 crystal structures of the human , , proteasome at improved resolutions ranging from 1.8 ¨ 2.2 A. These new crystal structures , of human 20S proteasomes provide insight into the inhibited state at atomic resolution. In ' contrast to the previously described formation of a 6-membered 1,4-morpholine ring structure , for epoxyketone proteasome inhibitors, it is now possible to visualize the formation of a 7-membered 1,4-oxazepane ring structure involving the catalytic threonine residue of the , proteasome active site and the inhibitor in the inhibited state. Formation of such an 1,4-oxazepane inhibited state is achieved by a double electrophilic reactive group on the inhibitor, where both electrophiles are in a distance of two atoms to one and another.
, This finding allows to propose a novel chemical mechanism for the inhibition of 20S
proteasomes by epoxyketone inhibitors. In this reaction mechanism, initially the y-hydroxyl , , group of the proteasome active site catalytic threonine reacts with the ketone moiety, similar to the situation where the 1,4-morpholine ring (6-ring) structure is formed.
In contrast to established theory, and to allow for 1,4-oxazepane 7-ring formation, the N-terminal amino group of Thr1 reacts in an irreversible manner with that carbon atom of the epoxide of the inhibitor which is in 3-position to the ketone (Scheme 2). The reaction with the carbon atom of the epoxide in 3-position to the ketone appears to be favored because it is the less , substituted center.
, , , Lys33,1 [9 NUK .. = NH2 0 e HO %0 1.06 HO
0 414... --N.
..., - .
-I-11....c H2 Thr2 I
% 0 .. .... A
HiN el iii 0 Thr2 R Alµ%4)1414 Thr2 HO i 4 3 i N
CAT
Scheme 2: Chemical reaction mechanism for the inhibition of proteasome active sites by epoxyketone inhibitors according to the invention and based on high resolution co-crystal ,
, , ' The present inventors determined more than 20 crystal structures of the human , , proteasome at improved resolutions ranging from 1.8 ¨ 2.2 A. These new crystal structures , of human 20S proteasomes provide insight into the inhibited state at atomic resolution. In ' contrast to the previously described formation of a 6-membered 1,4-morpholine ring structure , for epoxyketone proteasome inhibitors, it is now possible to visualize the formation of a 7-membered 1,4-oxazepane ring structure involving the catalytic threonine residue of the , proteasome active site and the inhibitor in the inhibited state. Formation of such an 1,4-oxazepane inhibited state is achieved by a double electrophilic reactive group on the inhibitor, where both electrophiles are in a distance of two atoms to one and another.
, This finding allows to propose a novel chemical mechanism for the inhibition of 20S
proteasomes by epoxyketone inhibitors. In this reaction mechanism, initially the y-hydroxyl , , group of the proteasome active site catalytic threonine reacts with the ketone moiety, similar to the situation where the 1,4-morpholine ring (6-ring) structure is formed.
In contrast to established theory, and to allow for 1,4-oxazepane 7-ring formation, the N-terminal amino group of Thr1 reacts in an irreversible manner with that carbon atom of the epoxide of the inhibitor which is in 3-position to the ketone (Scheme 2). The reaction with the carbon atom of the epoxide in 3-position to the ketone appears to be favored because it is the less , substituted center.
, , , Lys33,1 [9 NUK .. = NH2 0 e HO %0 1.06 HO
0 414... --N.
..., - .
-I-11....c H2 Thr2 I
% 0 .. .... A
HiN el iii 0 Thr2 R Alµ%4)1414 Thr2 HO i 4 3 i N
CAT
Scheme 2: Chemical reaction mechanism for the inhibition of proteasome active sites by epoxyketone inhibitors according to the invention and based on high resolution co-crystal ,
6 structures with human 20S proteasomes. Initially, the y-hydroxyl group of the active site catalytic threonine amino acid side chain esterifies the ketone group of the epoxyketone inhibitor by a nucleophilic attack (left). The nucleophilic attack results in the formation of a hemiketal intermediate, where the y-hydroxyl group of the active site catalytic threonine is reversibly bound to the epoxyketone inhibitor (middle). Until this step, the reaction mechanism for the formerly assumed 1,4-morpholine and the newly evidenced 1,4-oxazepane structures in the inhibited state are identical. For the formation of the 1,4-oxazepane structure, however, the N-terminal amino group of the active site catalytic threonine then reacts with the electrophilic carbon atom of the epoxide in 13-position to the ketone to form the covalently modified proteasome active site (right). This 1,4-oxazepane ring structure, which is formed by both the proteasome active site and the inhibitor results in an irreversible inhibition of the proteasome active site.
From a theoretical perspective, epoxyketone inhibitors are capable of forming either type of adduct, namely a 6-ring or a 7-ring. However, the formation of a 7-ring adduct has never been considered. Instead, the prior art is consistent in that a morpholine ring would be formed. The present inventors' work is first to establish that a 7-ring adduct is formed. As a consequence, the present inventors are the first to disclose the specific molecular architecture as laid down in formula (I) which is specifically tailored for the formation of a 7-ring adduct. The inhibitory activity of the art-established epoxyketones entirely fails to suggest this mechanism. Only in view of the high resolution crystal structures, the present inventors were able to discover the 6-regiospecificity of the nucleophilic attack of the active site threonine residue of the proteasome.
Without wishing to be bound to a specific theory, the present inventors furthermore consider that the formation of a seven ring adduct is kinetically favoured. Therefore, the provision of the compounds of the first aspect of the present invention which are specifically tailored for said kinetically favoured reaction mechanism will allow the use of lower dosages. As a consequence, fewer side effects are expected.
X is a functional group providing an electrophile. It can be a keto group, a thio-keto group or a boronic acid group. Deviant from the boronic acid group as present, for example, in Bortezomib, the compound of formula (I) requires that boron is part of the main chain. As shown in Scheme 2, the oxygen of the hydroxy group of the active site threonine residue of the proteasome binds to the electrophile atom in group X (the carbon atom or the boron atom).
From a theoretical perspective, epoxyketone inhibitors are capable of forming either type of adduct, namely a 6-ring or a 7-ring. However, the formation of a 7-ring adduct has never been considered. Instead, the prior art is consistent in that a morpholine ring would be formed. The present inventors' work is first to establish that a 7-ring adduct is formed. As a consequence, the present inventors are the first to disclose the specific molecular architecture as laid down in formula (I) which is specifically tailored for the formation of a 7-ring adduct. The inhibitory activity of the art-established epoxyketones entirely fails to suggest this mechanism. Only in view of the high resolution crystal structures, the present inventors were able to discover the 6-regiospecificity of the nucleophilic attack of the active site threonine residue of the proteasome.
Without wishing to be bound to a specific theory, the present inventors furthermore consider that the formation of a seven ring adduct is kinetically favoured. Therefore, the provision of the compounds of the first aspect of the present invention which are specifically tailored for said kinetically favoured reaction mechanism will allow the use of lower dosages. As a consequence, fewer side effects are expected.
X is a functional group providing an electrophile. It can be a keto group, a thio-keto group or a boronic acid group. Deviant from the boronic acid group as present, for example, in Bortezomib, the compound of formula (I) requires that boron is part of the main chain. As shown in Scheme 2, the oxygen of the hydroxy group of the active site threonine residue of the proteasome binds to the electrophile atom in group X (the carbon atom or the boron atom).
7 The group Y¨Z defines a second electrophile. Either Y as such or Y¨Z as a whole is electrophile; for preferred implementations see further below.
Moieties R2 and R3 define the intervening portion of the compound between the two electrophiles.
R1 is the above mentioned targeting moiety. Targeting moieties are known in the art. In many instances, targeting moieties are peptidic in nature. This applies, for example, to Epoxomicin, Oprozomib, Carfilzomib, Dihydroeponomycin, Eponemycin and ONX-0914. Since the active site of the proteasome exhibits proteolytic activity, peptides generally bind to said active site and are accordingly useful for targeting.
Said first group may optionally be bound to a second group which second group enhances delivery. To the extent the first group is peptidic in nature and consists of three amino acids or derivatives thereof, said second group may occupy a fourth position, in the art also referred to as S4 position. Dorsey et al. (J. Med. Chem., 51, 1068-1072 (2008)) and Zhou et al. (J. Med. Chem., 52, 3028-3038 (2009)) explored several suitable groups which are attached to the N-terminal end of a peptidic first group. These groups attached to the N-terminal end of a peptidic first group as described in these two publications all constitute suitable second groups in accordance with the present invention.
An alternative term for said second group is "N-cap".
While peptidic first groups are envisaged, the particular structure of the targeting group is not key to the present invention. Basically, any chemical group which provides for targeting to a proteolytic site in the proteasome or to the vicinity thereof is a suitable group R1 in accordance with the present invention. To the extent a targeting group does not target directly to the proteolytic site, but to another site of the proteasome in the vicinity of the proteolytic site, linkers of suitable length may be used to connect the targeting group R1 to the active element of the compound of the first aspect, said active element comprising groups X, Y and Z.
To give an example of alternative targeting groups, Beck et al. (Angew. Chem.
Int. Ed. 54, 11275-11278 (2015)) describe a molecule binding to the crevice between 01 and 62 subunit of the proteasome. This compound is displayed below.
Moieties R2 and R3 define the intervening portion of the compound between the two electrophiles.
R1 is the above mentioned targeting moiety. Targeting moieties are known in the art. In many instances, targeting moieties are peptidic in nature. This applies, for example, to Epoxomicin, Oprozomib, Carfilzomib, Dihydroeponomycin, Eponemycin and ONX-0914. Since the active site of the proteasome exhibits proteolytic activity, peptides generally bind to said active site and are accordingly useful for targeting.
Said first group may optionally be bound to a second group which second group enhances delivery. To the extent the first group is peptidic in nature and consists of three amino acids or derivatives thereof, said second group may occupy a fourth position, in the art also referred to as S4 position. Dorsey et al. (J. Med. Chem., 51, 1068-1072 (2008)) and Zhou et al. (J. Med. Chem., 52, 3028-3038 (2009)) explored several suitable groups which are attached to the N-terminal end of a peptidic first group. These groups attached to the N-terminal end of a peptidic first group as described in these two publications all constitute suitable second groups in accordance with the present invention.
An alternative term for said second group is "N-cap".
While peptidic first groups are envisaged, the particular structure of the targeting group is not key to the present invention. Basically, any chemical group which provides for targeting to a proteolytic site in the proteasome or to the vicinity thereof is a suitable group R1 in accordance with the present invention. To the extent a targeting group does not target directly to the proteolytic site, but to another site of the proteasome in the vicinity of the proteolytic site, linkers of suitable length may be used to connect the targeting group R1 to the active element of the compound of the first aspect, said active element comprising groups X, Y and Z.
To give an example of alternative targeting groups, Beck et al. (Angew. Chem.
Int. Ed. 54, 11275-11278 (2015)) describe a molecule binding to the crevice between 01 and 62 subunit of the proteasome. This compound is displayed below.
8 o K
0. N
c . 441ii Replacing the ethyl group of the ethoxy moiety bound to the phenyl group of said compound is a means of rendering this molecule suitable group R1. This is explained in further detail below.
The term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention. Suitable pharmaceutically acceptable salts include acid addition salts which may, for example, be formed by mixing a solution of compounds of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compound carries an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., ammonium, quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sulfonate).
Illustrative examples of pharmaceutically acceptable salts include, but are not limited to, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, 2-naphthalenesulfonate, napsylate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate/diphosphate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate,
0. N
c . 441ii Replacing the ethyl group of the ethoxy moiety bound to the phenyl group of said compound is a means of rendering this molecule suitable group R1. This is explained in further detail below.
The term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention. Suitable pharmaceutically acceptable salts include acid addition salts which may, for example, be formed by mixing a solution of compounds of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compound carries an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., ammonium, quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sulfonate).
Illustrative examples of pharmaceutically acceptable salts include, but are not limited to, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, 2-naphthalenesulfonate, napsylate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate/diphosphate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate,
9 sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, undecanoate, valerate, and the like (see, for example, S. M. Berge et al., "Pharmaceutical Salts", J. Pharm, Sc., 66, pp. 1-19 (1977)).
When the compounds of the present invention are provided in crystalline form, the structure can contain solvent molecules. The solvents are typically pharmaceutically acceptable solvents and include, among others, water (hydrates) or organic solvents.
Examples of possible solvates include ethanolates and iso-propanolates.
The term "codrug" refers to two or more therapeutic compounds bonded via a covalent chemical bond. A detailed definition can be found, e.g., in N. Das et al., European Journal of Pharmaceutical Sciences, 41, 2010, 571-588.
The term "cocrystal" refers to a multiple component crystal in which all components are solid under ambient conditions when in their pure form. These components co-exist as a stoichiometric or non-stoichometric ratio of a target molecule or ion (i.e., compound of the present invention) and one or more neutral molecular cocrystal formers. A
detailed discussion can be found, for example, in Ning Shan et al., Drug Discovery Today, 13(9/10), 2008, 440-446 and in D. J. Good et al., Cryst. Growth Des., 9(5), 2009, 2252-2264.
The compounds of the present invention can also be provided in the form of a prodrug, namely a compound which is metabolized in vivo to the active metabolite.
Suitable prodrugs are, for instance, esters. Specific examples of suitable groups are given, among others, in US 2007/0072831 in paragraphs [0082] to [0118] under the headings prodrugs and protecting groups.
To the extent compounds of the invention exhibit a pH-dependent charged state, it is understood that all possible charged states are embraced. A preferred pH range in this regard is from 0 to 14.
To the extent a compound according to the invention bears a net charge, it is understood that the compound is provided in electroneutral form. This is achieved by one or more counterions, preferred counterions being defined in relation to the term "salt" herein above.
In a preferred embodiment, said first group is a peptidic group comprising or consisting of at least two amino acids, or a corresponding peptidomimetic, wherein X takes the place of the carbonyl group or of the a-carbon of the C-terminal amino acid of said peptidic group, and said second group, if present, is bound to the N-terminus of said peptidic group.
Preferred amino acids are a-amino acids. Preferred a-amino acids are the 20 proteinogenic amino acids. Also preferred are derivatives of said proteinogenic amino acids, for example, the methyl ester of serine, also denoted "Ser(OMe)". Other derivatives of the proteinogenic amino acids may be used as well, for example those described in Zhou et al.
/oc. cit. and including 4-diazolyl-alanine, homoserine methyl ester, pyridyl alanines such as 2-pyridyl alanine, 3-pyridyl alanine and 4-pyridyl alanine; 3-thienyl alanine, cyclohexyl alanine, cyano alanine and methyl serine.
Also other a-amino acids such as 2-amino butyric acid may be used.
In further preferred embodiments, 8-amino acids may be used in one or more positions of the peptidic group. Also preferred is to use D-amino acids at one or more positions.
As an alternative to peptide bonds, alternative functional groups may be used.
This may apply to a single peptide bond or to two or more peptide bonds. If all peptide bonds are replaced by other functional groups, the backbone chemistry in its entirety is changed.
Alternative backbones are known in the art and include polyactide (PLA), alkylamines, jeffamines and those shown below ((a) to (r)) and described in Grimm et al.
(Acta Cryst D
(2010), 66, 685-697).
i I
I
I
i i 0 0 X k 1i 112 i k ....,_ __ ......
\
0 ___________ 1 Otz,..' I
s'''..."...10 0 i i i es t 1 Sk ./
--:- .. p 0 , \
f t i , 0 .... -, 1.: 1 ;
, X .
i X X
(-- __________________________________ 0..
0 ... ): s 0 () 0 ' g..1 d =====
., X frirOZ
Z
(.... I t i ..... I. __ N
X
Z
.
1.---: F¨
.*: ¨1 i ;
(!) .
:
,:....
.....õ
-----"-------ik te L........___ ..._____J .t o I
, , i :
t ;
s I
i i ;
i Z
i ;
, i fil s., f i I
9--- =-.
k , o i I
o i t !
' i I
I
,=-=., ...,==='f'.2\.......H._______I
er, 0 , t :
t e;
.a.
....
Z W
4.
, .
.
X
X X
.it) :Ci .--.
Y ____________________________ 0 ...
, . :...7. x cr"
x _ (II:3 I I
, The above displayed backbones are as follows.
(a) M-type Jeffamines. R1 = ¨H for ethylene oxide (EO) or ¨CH3 for propylene oxide (PO).
The P0/E0 molar ratio is 29/6 for Jeffamine M2005, 10/31 for Jeffamine M2070 and 9/1 for Jeffamine M600. (b) Pentaerythritol ethoxylate. (c) Pentaerythritol propoxylate. (d) Polyvinyl pyrrolidone. (e) Polypropylene glycol. (f) Polyvinyl alcohol. (g) Polyacrylate. (h) Cellulose -based polymers. R1 = ¨H, ¨CH3 or ¨CH2CHOHCH3 (hydroxypropyl methylcellulose), ¨H
or CH2CO2H (carboxymethyl cellulose). (i) Poly(ethylene imine). (j) Di[poly(ethyleneglycol)]
adipate. (k) Jeffamine ED2003. (I) Jeffamine D2000. (m) Jeffamine SD2001. (n) T-type Jeffamines. (o) Polyacryl amide. (p) Glycerol ethoxylate. (q) Acrylic acid/maleic acid copolymer. (r) Vinylpyrrolidone/vinylimidazole copolymer. Each of the indices x, y, z and w is independently chosen from the integer numbers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and
When the compounds of the present invention are provided in crystalline form, the structure can contain solvent molecules. The solvents are typically pharmaceutically acceptable solvents and include, among others, water (hydrates) or organic solvents.
Examples of possible solvates include ethanolates and iso-propanolates.
The term "codrug" refers to two or more therapeutic compounds bonded via a covalent chemical bond. A detailed definition can be found, e.g., in N. Das et al., European Journal of Pharmaceutical Sciences, 41, 2010, 571-588.
The term "cocrystal" refers to a multiple component crystal in which all components are solid under ambient conditions when in their pure form. These components co-exist as a stoichiometric or non-stoichometric ratio of a target molecule or ion (i.e., compound of the present invention) and one or more neutral molecular cocrystal formers. A
detailed discussion can be found, for example, in Ning Shan et al., Drug Discovery Today, 13(9/10), 2008, 440-446 and in D. J. Good et al., Cryst. Growth Des., 9(5), 2009, 2252-2264.
The compounds of the present invention can also be provided in the form of a prodrug, namely a compound which is metabolized in vivo to the active metabolite.
Suitable prodrugs are, for instance, esters. Specific examples of suitable groups are given, among others, in US 2007/0072831 in paragraphs [0082] to [0118] under the headings prodrugs and protecting groups.
To the extent compounds of the invention exhibit a pH-dependent charged state, it is understood that all possible charged states are embraced. A preferred pH range in this regard is from 0 to 14.
To the extent a compound according to the invention bears a net charge, it is understood that the compound is provided in electroneutral form. This is achieved by one or more counterions, preferred counterions being defined in relation to the term "salt" herein above.
In a preferred embodiment, said first group is a peptidic group comprising or consisting of at least two amino acids, or a corresponding peptidomimetic, wherein X takes the place of the carbonyl group or of the a-carbon of the C-terminal amino acid of said peptidic group, and said second group, if present, is bound to the N-terminus of said peptidic group.
Preferred amino acids are a-amino acids. Preferred a-amino acids are the 20 proteinogenic amino acids. Also preferred are derivatives of said proteinogenic amino acids, for example, the methyl ester of serine, also denoted "Ser(OMe)". Other derivatives of the proteinogenic amino acids may be used as well, for example those described in Zhou et al.
/oc. cit. and including 4-diazolyl-alanine, homoserine methyl ester, pyridyl alanines such as 2-pyridyl alanine, 3-pyridyl alanine and 4-pyridyl alanine; 3-thienyl alanine, cyclohexyl alanine, cyano alanine and methyl serine.
Also other a-amino acids such as 2-amino butyric acid may be used.
In further preferred embodiments, 8-amino acids may be used in one or more positions of the peptidic group. Also preferred is to use D-amino acids at one or more positions.
As an alternative to peptide bonds, alternative functional groups may be used.
This may apply to a single peptide bond or to two or more peptide bonds. If all peptide bonds are replaced by other functional groups, the backbone chemistry in its entirety is changed.
Alternative backbones are known in the art and include polyactide (PLA), alkylamines, jeffamines and those shown below ((a) to (r)) and described in Grimm et al.
(Acta Cryst D
(2010), 66, 685-697).
i I
I
I
i i 0 0 X k 1i 112 i k ....,_ __ ......
\
0 ___________ 1 Otz,..' I
s'''..."...10 0 i i i es t 1 Sk ./
--:- .. p 0 , \
f t i , 0 .... -, 1.: 1 ;
, X .
i X X
(-- __________________________________ 0..
0 ... ): s 0 () 0 ' g..1 d =====
., X frirOZ
Z
(.... I t i ..... I. __ N
X
Z
.
1.---: F¨
.*: ¨1 i ;
(!) .
:
,:....
.....õ
-----"-------ik te L........___ ..._____J .t o I
, , i :
t ;
s I
i i ;
i Z
i ;
, i fil s., f i I
9--- =-.
k , o i I
o i t !
' i I
I
,=-=., ...,==='f'.2\.......H._______I
er, 0 , t :
t e;
.a.
....
Z W
4.
, .
.
X
X X
.it) :Ci .--.
Y ____________________________ 0 ...
, . :...7. x cr"
x _ (II:3 I I
, The above displayed backbones are as follows.
(a) M-type Jeffamines. R1 = ¨H for ethylene oxide (EO) or ¨CH3 for propylene oxide (PO).
The P0/E0 molar ratio is 29/6 for Jeffamine M2005, 10/31 for Jeffamine M2070 and 9/1 for Jeffamine M600. (b) Pentaerythritol ethoxylate. (c) Pentaerythritol propoxylate. (d) Polyvinyl pyrrolidone. (e) Polypropylene glycol. (f) Polyvinyl alcohol. (g) Polyacrylate. (h) Cellulose -based polymers. R1 = ¨H, ¨CH3 or ¨CH2CHOHCH3 (hydroxypropyl methylcellulose), ¨H
or CH2CO2H (carboxymethyl cellulose). (i) Poly(ethylene imine). (j) Di[poly(ethyleneglycol)]
adipate. (k) Jeffamine ED2003. (I) Jeffamine D2000. (m) Jeffamine SD2001. (n) T-type Jeffamines. (o) Polyacryl amide. (p) Glycerol ethoxylate. (q) Acrylic acid/maleic acid copolymer. (r) Vinylpyrrolidone/vinylimidazole copolymer. Each of the indices x, y, z and w is independently chosen from the integer numbers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and
10, provided that a minimal length of at least two, preferably three building blocks is obtained. While branched backbones such as those depicted in (b) and (c) are not excluded, preference is .. given to backbones which are not branched. Accordingly, in the formulae for branched backbones such as (b) and (c), preference is given to two indices selected from x, y and z being 0. Potential positions for amino acid side chains are denoted as ellipses in the figure.
These positions correspond to the Ca atmons in a peptide.
More generally speaking, the peptidic group may be replaced by a corresponding peptidomimetic. The term "corresponding" in this context means that the peptidomimetic has similar size when compared to a peptidic group. Accordingly, a peptidic group consisting of two amino acids and a peptidic group consisting of three amino acids, respectively, each impose size limits on a corresponding peptidomimetic. A peptidomimetic in accordance with the present invention may use the above mentioned alternative backbones and/or any of the mentioned non-proteinogenic amino acids, noting that amino group and/or carboxylic group of any non-proteinogenic amino acid may be further modified in order to account for the mentioned alternative backbone.
In terms of secondary structure, preference is given to peptidic groups, corresponding peptidomimetics or backbones which are capable of assuming a 13-sheet structure. Specific backbones capable of assuming a I3-sheet structure include peptide bonds and the alternatives described above.
As disclosed above, X may take the place of the carbonyl group of the a carbon of the C-terminal amino acid of said peptidic group. In other words, and assuming that X is CO which is preferred, X is the carbonyl group of said C-terminal amino acid. In the alternative, the a-carbon may be replaced with X. In that case, the C-terminal amino acid of said peptidic group may be viewed as a truncated amino acid. Having said that, it is formally considered as a separate building block and is also referred to as S1 site of the proteasome inhibitor.
The term "peptidic" refers to peptide bonds connecting the amino acids of said group. The C-terminal end of the peptidic group is the end which is connected to X. To the extent the peptide bonds are inverted, i.e. NHCO instead of CONH, this is a preferred embodiment falling under the term "peptidomimetic".
Detailed exemplary synthesis procedures for two preferred compounds are given in the examples. In the following, general synthesis procedures are disclosed.
Synthesis of active ester: A) Beta-Keto acid formation from Boc-L-amino acid, esterification for the protection of beta-carboxyl moiety. B) Methylation reaction. C) Boc-Deprotection. D) Peptide coupling. E) Saponification of ester to Beta-Keto acid (partially instable). F) Preparation of an active ester with N-Hydroxysuccinirnide.
Synthesis of a Beta-Ketoaldehyde: G) Preparation of a Weinreb-Amide from Boc-L-amino acid. H) Gringard reaction to obtain alpha-Dioxacyclopentyl Ketone.
Methylation Reaction. I) Boc-Deprotection. J) Peptide coupling. K) Oxidation to Beta-Ketoaldehyde.
Tripeptide Synthesis: L) Protection of the carboxyl group of Boc-L-Amino Acid by esterification. M) Boc-Deprotection. N) Peptide coupling with Boc-L-amino acid. 0) Boc-Deprotection. P) Coupling with N-cap acid. Q) Saponification of ester to acid.
As an alternative to R1 being a peptidic group or a peptidomimetic, a group binding between subunits 131 and 132 of the proteasome may be used. Preferably, said group is an aryl sulfonamide, aryl preferably being phenyl, aryl being connected to R12 as defined in the following. Between said aryl sulfonamide and R12 further moieties may be present, said further moieties preferably being isosteric with the corresponding moieties of the particularly preferred group binding between subunits 131 and 132 as disclosed in the following. Particuarly preferred is that said group binding between subunits 131 and 132 is 442-(4-R12-oxy-phenyl) quinolin-4-y1 carboxamido] benzene N-acetyl sulfonamide. R12 is a linker connecting said group binding between subunits 131 and 132 to X, preferably being C5 to C10 alkyl, C5 to C10 alkenyl or ¨[0-(CH2)2]1-5, wherein one or more C atoms in said linker may be replaced with 0 and/or N.
Said alkenyl group may comprise one, two or more double bonds.
So far, the group Y¨Z has been displayed as a double bond, wherein one of the two bonds comprised in the double bond is dashed. This indicates that Y and Z may either be connected by a double bond or a single bond.
In a preferred embodiment, Y¨Z is Y=Z, and preferably selected from CH=0 or CH=CH2. In an alternative, Y¨Z is Y¨Z and is preferably selected from CH2-1, CH2-Br, CH2-CI, CH2-OPO(OH)2, CH2-0Ts or CO-NHS wherein OTs is p-toluene sulfonyloxy and NHS is N-oxy-succinimide. As an alternative to the NHS-activated ester, also other activated esters known in the art may be used.
In a further alternative preferred embodiment, Y¨Z is Y¨Z and preferably selected from 0-1, 0-Br, 0-CI, S-1, S-Br and S-I.
In a further preferred embodiment, R2 and R3 are identical and preferably methyl, H, methoxy or ¨CH2OH. Particularly preferred is that both R2 and R3 are methyl or that both R2 and R3 are H. Especially preferred is that both R2 and R3 are methyl.
Preferred is that X is CO.
Preferred is that Y¨Z is CH=0. Also preferred is that Y¨Z is CO-NHS.
Particularly preferred is that X is C=0 and Y¨Z is CH=0 or CO-NHS.
Particularly preferred is that X is C=0 and Y¨Z is CH=0 or CO-NHS and both R2 and R3 are methyl.
The following preferred embodiments are dedicated to preferred implementations of the targeting moiety R1. Any of the preferred embodiments of R1 can be combined with any of the preferred embodiments of X, Y, Z, R2 and R3.
In a preferred embodiment, said peptidic group consists of three a-amino acids, wherein preferably (a) the N-terminal amino acid is selected from Ser(OMe), Leu, Phe and Ala; the middle amino acid is selected from Ser(OMe), Leu, Phe and Ala; and/or the C-terminal amino acid is selected from Phe, Tyr, Leu, Ser(OMe) and Ala; or (b) said peptidic group consists of Ser(OMe)-Ser(OMe)-Phe, Leu-Leu-Tyr or Ala-Ala-Ala.
Said N-terminal amino acid is also referred to as the moiety defining the S3 site of the inhibitor. Said middle amino acid defines the S2 site. Said C-terminal amino acid defines the S1 site.
In a further preferred embodiment, said group enhancing delivery is present and is R11-00, !I .-01 -CS-, or R11-S02-, R11 being selected from the following substituted or unsubstituted groups, groups being carbocyclyl, heterocarbocyclyl, carbocyclyl alkyl, heterocarbocyclyl alkyl, alkyl heterocarbocyclyl alkoxy heterocarbocyclyl, alkoxyalkyl heterocarbocyclyl, heterocarbocyclyl amino, heterocarbocyclyl alkyl heterocarbocyclyl, and alkyl heterocarbocyclyl alkyl heterocarbocyclyl, wherein alkyl is C1 to C4 alkyl, preferably methyl, substituents are C1 to C4 alkyl, preferably methyl or ethyl, C1 to C4 alkoxy, preferably methoxy or ethoxy, hydroxy and/or halogen, preferably Cl, Br or I, and heteroatoms are 0, N and/or S.
R11-CO is particularly preferred.
R11 being heterocarbocyclyl is particularly preferred.
The term "carbocyclyl" designates a ring molecule, wherein the ring comprises carbon atoms.
The ring may be formed exclusively by carbon atoms, but does not have to.
Accordingly, one, two or more heteroatoms may be present. The ring may be saturated in which case it would be a cyclic alkane, optionally comprising one or more heteroatoms. The ring may contain one, two or more double bonds. If said double bonds are conjugated, carbocyclyl is an aryl moiety.
In a particularly preferred embodiment, (a) said carbocyclyl is aryl or biaryl, aryl being monocyclic or bicyclic and preferably phenyl or naphthyl; and (b) said heterocarbocyclyl is heteroaryl, heteroaryl being monocyclic or bicyclic, bi-heteroaryl, aryl heteroaryl, heteroaryl aryl or heterocycloalkyl, heteroaryl preferably being furyl, thienyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, pyridinyl, pyrazinyl, pyridazinyl or quinolinyl, aryl preferably being phenyl, heterocycloalkyl preferably being morpholinyl or tetrahydrofuranyl.
Particularly preferred is that heterocarbocyclyl is heteroaryl, in particular monocyclic heteroaryl.
In a particularly preferred embodiment R11 is selected from 2-methyl thiazol-5-y1; 4-morpholinyl methyl; 1,4-dichloro 2-phenyl; 6-phenylpyridin-2-y1; pyrazin-2-y1;
3-furyl; 2-thienyl;
5-oxazoly1; 5-isoxazoly1; (5-Me)-3-isoxazoly1; (5-iPr)-3-isoxazoly1; (5-MeOCH2)-3-isoxazoly1;
3-pyrazoly1; 2-imidazoly1; (N-Me)-3-pyrazoly1; (N-Me)-2-imidazoly1; (5-Me)-3-pyrazoly1; 4-pyridinyl; 4-pyridazinyl; 2-(R)-tetrahydrofuranyl; 2-(S)-tetrahydrofuranyl; (5-Me)-3-isoxazolyl-NH-; pyrazin-2-y1; naphth-2-y1; quinolin-2-y1; 4-biphenyl; 3-biphenyl; 4-phenylpyridin-2-y1; 3-phenyl-pyridin-2-y1; 5-phenylpyrazin-2-y1; 6-phenylpyrazin-2-y1; 2-phenyl-thiazol-4-y1; and 5-R111-isoxazol-3-y1;
wherein RII' is selected from methyl, 4-morpholinyl methyl, 1,2,4-triazoly1 methyl, imidazolyl methyl and N-methyl piperazinyl methyl.
Especially preferred is that R11 is 2-methyl thiazol-5-yl.
Especially preferred compounds of the first aspect are the compounds of formulae (11a) and (11b):
R
R 1 ).HO
(11a) (11b), wherein R1 is R11-CO-Ser(OMe)-Ser(OMe)-NH-CH(CH2-C6H5), R11 being as defined above, and wherein most preferably R1 is 2-methyl thiazol-5-y1 carbonyl Ser(OMe)-Ser(OMe)-NH-CH(CH2-C6H5).
In a second aspect, the present invention provides the use of a compound as defined in the first aspect as a proteasome inhibitor.
One or a plurality of compounds in accordance with the first aspect may be used.
Preferably, said proteasome is a proteasome core particle (CP) which is also known as 20S
proteasome. In a preferred embodiment, the constitutive core particle (cCP) is used.
Alternatively, tissue-specific proteasomal subtypes such as immunoproteasome (iCP) or the thymusproteasome (tCP) may be used.
A proteasome inhibitor in accordance with the present invention is a compound which inhibits one or more proteolytic activities of a proteasome. A proteasome comprises a plurality of proteolytic sites. Preferably, said proteolytic sites are as follows: a site with caspase-like proteolytic activity, a site with trypsin-like proteolytic activity and a site with chymotrypsin-like proteolytic activity. Proteasome inhibitors in accordance with the present invention are capable of inhibiting at least one of these sites. Preferred are compounds which are capable of inhibiting two or all three of these sites.
Related thereto, the present invention provides, in a third aspect, a method of inhibiting a proteasome, said method comprising bringing into contact a proteasome and a compound as defined in the first aspect, provided that methods for treatment of the human or animal body by therapy and diagnostic methods practised on the human or animal body are excluded and/or said method is performed in vitro or ex vivo.
Also provided is a method of inhibiting a proteasome, said method comprising bringing into contact a proteasome and a compound as defined in the first aspect. The method may be performed in vivo.
It is understood that said bringing into contact is effected under conditions which allow a physical contact between said compound and the proteasome. Suitable conditions include aqueous solutions, such as buffered aqueous solutions. Exemplary conditions can be found in the examples enclosed herewith.
The examples include also a proteasome activity assays in accordance with the invention.
A preferred proteasome activity assay is as follows. The activity assay is based on the cleavage of 7-amino-4-methyl-coumarin (AMC) substrates consisting of the fluorophore AMC
fused N-terminal to a peptide backbone. These substrates are fluorogenic as the cleaved AMC exhibits fluorescence (emission wavelength: 380 nm; emission wavelength:
460 nm).
For every active site a specific substrate is used (LLVY-AMC for the chymotryptic-like site, LLE-AMC for the caspase-like site, and RLR-AMC for the tryptic-like site).
Proteasome activity is monitored by first mixing inhibitor and substrate simultaneously in assay buffer and incubation for 3 min at 37C . After the addition of 50 nM proteasome and mixing, the increase in fluorescence (excitation wavelength: 380 nm; emission wavelength:
460 nm) is monitored with a spectrofluorimeter. DMSO concentration is kept for all measurements.
The fluorescence readout correlates with proteasome activity. This procedure is utilized to determine the first-order rate constant of inhibition. The IC50, which refers to the inhibitor concentration needed to decrease enzyme activity by 50%, can be determined by measuring proteasome activity at varying inhibitor concentrations.
In a fourth aspect, the present invention provides a medicament or lead compound for developing a medicament comprising or consisting of a compound as defined in the first aspect.
The terms "medicament" and "pharmaceutical composition" are used equivalently herein. A
pharmaceutical composition in accordance with the present invention may comprise a pharmaceutically acceptable carrier, diluent or excipient.
Examples of suitable pharmaceutically acceptable carriers, excipients and/or diluents are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods.
These pharmaceutical compositions can be administered to the subject at a suitable dose.
Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration. It is particularly preferred that said administration is carried out by injection. The compositions may also be administered directly to the target site, e.g., by biolistic delivery to an external or internal target site. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
Pharmaceutically active matter may be present in amounts between 1 ng and 10 mg/kg body weight per dose;
however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. If the regimen is a continuous infusion, it should also be in the range of 1 pg to 10 mg units per kilogram of body weight per minute. Preferred doses are in the range from about 10 to about 40 mg/m2 body surface, which correspond to about 0.25 to about 1 mg/kg body weight.
One or more compounds in accordance with the first aspect of the present invention may be the only pharmaceutically active agent(s) comprised in a medicament in accordance with the present invention. Alternatively, one, two or more further pharmaceutically active agents may be present. Said further pharmaceutically active agents are preferably selected from known proteasome inhibitors and/or therapeutic agents for the treatment of multiple myeloma.
Known proteasome inhibitors are discussed above and include bortezomib, carfilzomib, ixazomib, marizomib, oprozomib, delanzomib, epoxomicin, dihydroeponemycin.
Exemplary agents for the treatment of multiple myeloma are lenalidomide and dexamethasone as well as the combination of the latter two.
The development of a lead compound into a medicament is also known as lead optimization.
Methods for the optimization of the pharmacological properties of lead compounds are known in the art and comprise a method of modifying a lead compound to achieve: (i) modified site of action, spectrum of activity, organ specificity, and/or (ii) improved potency, and/or (iii) decreased toxicity (improved therapeutic index), and/or (iv) decreased side effects, and/or (v) modified onset of therapeutic action, duration of effect, and/or (vi) modified pharmacokinetic parameters (resorption, distribution, metabolism and excretion), and/or (vii) modified physico-chemical parameters (solubility, hygroscopicity, color, taste, odor, stability, state), and/or (viii) improved general specificity, organ/tissue specificity, and/or (ix) optimized application form and route by (i) esterification of carboxyl groups, or (ii) esterification of hydroxyl groups with carboxylic acids, or (iii) esterification of hydroxyl groups to, e.g.
phosphates, pyrophosphates or sulfates or hemi-succinates, or (iv) formation of pharmaceutically acceptable salts, or (v) formation of pharmaceutically acceptable complexes, or (vi) synthesis of pharmacologically active polymers, or (vii) introduction of hydrophilic moieties, or (viii) introduction/exchange of substituents on aromates or side chains, change of substituent pattern, or (ix) modification by introduction of isosteric or bioisosteric moieties, or (x) synthesis of homologous compounds, or (xi) introduction of branched side chains, or (xii) conversion of alkyl substituents to cyclic analogues, or (xiii) derivatisation of hydroxyl group to ketales, acetales, or (xiv) N-acetylation to amides, phenylcarbamates, or (xv) synthesis of Mannich bases, imines, or (xvi) transformation of ketones or aldehydes to Schiff's bases, oximes, acetales, ketales, enolesters, oxazolidines, .. thiazolidines or combinations thereof.
The various steps recited above are generally known in the art. They include or rely on quantitative structure-action relationship (QSAR) analyses (Kubinyi, "Hausch-Analysis and Related Approaches", VCH Verlag, Weinheim, 1992), combinatorial biochemistry, classical chemistry and others (see, for example, Holzgrabe and Bechtold, Deutsche Apotheker Zeitung 140(8), 813-823, 2000).
In a fifth aspect, the present invention provides a compound as defined in the first aspect for use in a method of treating, ameliorating or preventing cancer, an autoimmune disease, muscular dystrophy, emphysema, or cachexia accompanying cancer or AIDS.
More generally speaking, the compounds in accordance with the invention are useful in methods of treating, ameliorating or preventing any condition which is amenable to treatment, prevention or amelioration via inhibition of a proteasome.
In a preferred embodiment, said cancer is a lymphoid malignancy, preferably selected from multiple myeloma (MM) including relapsed and refractory MM; non-Hodgkin lymphoma such as B-cell lymphomas including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), and Waldenstrom macroglobulinaemia.
In a further preferred embodiment said autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, Sjorgen's syndrome or scleroderma.
In a sixth aspect, the present invention provides a method of identifying a compound capable of inhibiting a proteasome, said method comprising bringing into contact a test compound of formula (III) X -(III), wherein R4 is an organic group, and X, Y, Z, R2 and R3 are as defined in accordance with the first aspect or preferred embodiments thereof, with a proteasome, wherein a decreased activity of the proteasome in presence of said test compound as compared to the absence thereof is indicative of said test compound being a compound capable of inhibiting a proteasome.
This aspect relates to a screening method. Screening may be a biochemical screen or a cellular screen. Generally speaking, a variety of assay designs are available for the purpose of identifying compounds which are capable of inhibiting the activity of a given target molecule, here a proteasome. One of the established distinctions is between cellular assays and biochemical assays. Cellular assays are sometimes viewed as mimicking closer the in vivo situation, however, they suffer from the drawback that any candidate compound generally has to pass the cell membrane in a first step. Biochemical assays are simpler in that respect. The target, here a proteasome, may be presented in enriched or purified form in aqueous solution. In such an assay scenario there is no membrane barrier. The conditions, though, may be further remote from the environment in the organism to be subjected to therapy.
A negative control for the screen is the absence of any test compound as disclosed above.
As positive controls one or more compounds in accordance with the first aspect or known proteasome inhibitors as disclosed herein may be used.
As known in the art, screening methods may be implemented in a high throughput fashion.
Accordingly, said method may be effect in a high throughput format. High throughput assays generally may be performed in wells of microtiter plates, wherein each plate may contain 96, 384 or 1,536 wells. Handling of the plates, including incubation at temperatures other than ambient temperature, and bringing into contact of these compounds with the assay mixture is preferably effected by one or more computer controlled robotic systems including pipetting devices. In case large libraries of test compounds are to be screened and/or screening is to be effected within short time, mixture of, for example 10, 20, 30, 40, 50 or 100 test compounds may be added to each well. In case a well exhibits biological activity, in the present case inhibition of a proteasome, said mixture of test compounds may be de-convoluted to identify one or more test compounds in said mixture giving rise to said activity.
A compound capable of inhibiting a proteasome is also referred to as proteasome inhibitor.
Inhibition preferably amounts a decrease of activity of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%.
Further preferred is a 102-fold, 103-fold, 104-fold, 105-fold, 108-fold, 107-fold, 108-fold or 109-fold reduction of activity.
An art-established measure of inhibitory activity is the IC50 value which is the inhibitor concentration where 50% inhibition occurs. Preferably, proteasome inhibitors to be identified by the method of identifying of the present invention as well as compounds in accordance with the first aspect exhibit IC50 values in the one digit pM range, preferably below 1 pM, more preferably below 100 nM, below 10 nM, below 1 nM, or below 100 pM. IC50 values are preferably determined using the proteasome activity assay as described above.
In accordance with the method of the sixth aspect, R4 is not particularly limited. In fact, one of the applications of this method is the identification of further targeting moieties which targeting moieties may be different from the targeting moieties defined in relation to the first aspect of the invention.
As noted above, R4 is an organic group. It may have a molecular weight between 200 and 1,000 Da.
In a preferred embodiment, said activity is a proteolytic activity, preferably selected from caspase-like, trypsin-like and chymotrypsin-like activity.
In a further preferred embodiment said proteasome is comprised in an in vitro or ex vivo cell.
This preferred embodiment refers to a cellular assay.
A preferred cellular assay is as follows. Cells (e.g. HEK 293) are transfected with the pZsProSensor-1 vector (Clontech Laboratories, Inc.), a reporter gene construct for proteasomal activity. This vector encodes for a destabilized green fluorescent protein variant (ZsGreen) fused C-terminally to a specific degradation motif mediating the recognition and degradation by the proteasome. The fluorescence readout (excitation wavelength: 493 nm;
emission wavelength: 505 nm) of expressed ZsGreen is used to monitor proteasome activity.
Inhibition of the proteasome causes accumulation of ZsGreen correlating with an increased fluorescence signal in the GFP channel.
In a seventh aspect, the present invention provides a compound of formula (IV) X
Z
(IV), wherein A is selected from NH-NH2, N3 and a click chemistry functional group;
X, Y, Z, R2 and R3 are as defined above.
In an eighth aspect, the present invention provides the use of a compound of formula (IV) X
Z
(IV), wherein A is selected from NH-N H2, N3 and a click chemistry functional group;
X, Y, Z, R2 and R3 are as defined above;
in the synthesis of a proteasome inhibitor, of a pharmaceutically active agent or of a lead compound for the development of a pharmaceutically active agent, said pharmaceutically active agent preferably being for use in a method of treating or preventing cancer or an autoimmune disease.
The latter two aspects of the invention are directed to the headgroup or warhead of proteasome inhibitors in accordance with the present invention.
Generally speaking, A is a reactive group. Art-established reactive groups may be used. The purpose of A is to provide robust irreversible coupling to targeting moieties such as R1 as defined above. The reactive group A may be used for coupling to any targeting moiety. Upon coupling to a targeting moiety, compounds in accordance with the first aspect may be obtained.
"Click-chemistry is an art-established term; see e.g. Kolb et al. (2001) Click chemistry:
diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40
These positions correspond to the Ca atmons in a peptide.
More generally speaking, the peptidic group may be replaced by a corresponding peptidomimetic. The term "corresponding" in this context means that the peptidomimetic has similar size when compared to a peptidic group. Accordingly, a peptidic group consisting of two amino acids and a peptidic group consisting of three amino acids, respectively, each impose size limits on a corresponding peptidomimetic. A peptidomimetic in accordance with the present invention may use the above mentioned alternative backbones and/or any of the mentioned non-proteinogenic amino acids, noting that amino group and/or carboxylic group of any non-proteinogenic amino acid may be further modified in order to account for the mentioned alternative backbone.
In terms of secondary structure, preference is given to peptidic groups, corresponding peptidomimetics or backbones which are capable of assuming a 13-sheet structure. Specific backbones capable of assuming a I3-sheet structure include peptide bonds and the alternatives described above.
As disclosed above, X may take the place of the carbonyl group of the a carbon of the C-terminal amino acid of said peptidic group. In other words, and assuming that X is CO which is preferred, X is the carbonyl group of said C-terminal amino acid. In the alternative, the a-carbon may be replaced with X. In that case, the C-terminal amino acid of said peptidic group may be viewed as a truncated amino acid. Having said that, it is formally considered as a separate building block and is also referred to as S1 site of the proteasome inhibitor.
The term "peptidic" refers to peptide bonds connecting the amino acids of said group. The C-terminal end of the peptidic group is the end which is connected to X. To the extent the peptide bonds are inverted, i.e. NHCO instead of CONH, this is a preferred embodiment falling under the term "peptidomimetic".
Detailed exemplary synthesis procedures for two preferred compounds are given in the examples. In the following, general synthesis procedures are disclosed.
Synthesis of active ester: A) Beta-Keto acid formation from Boc-L-amino acid, esterification for the protection of beta-carboxyl moiety. B) Methylation reaction. C) Boc-Deprotection. D) Peptide coupling. E) Saponification of ester to Beta-Keto acid (partially instable). F) Preparation of an active ester with N-Hydroxysuccinirnide.
Synthesis of a Beta-Ketoaldehyde: G) Preparation of a Weinreb-Amide from Boc-L-amino acid. H) Gringard reaction to obtain alpha-Dioxacyclopentyl Ketone.
Methylation Reaction. I) Boc-Deprotection. J) Peptide coupling. K) Oxidation to Beta-Ketoaldehyde.
Tripeptide Synthesis: L) Protection of the carboxyl group of Boc-L-Amino Acid by esterification. M) Boc-Deprotection. N) Peptide coupling with Boc-L-amino acid. 0) Boc-Deprotection. P) Coupling with N-cap acid. Q) Saponification of ester to acid.
As an alternative to R1 being a peptidic group or a peptidomimetic, a group binding between subunits 131 and 132 of the proteasome may be used. Preferably, said group is an aryl sulfonamide, aryl preferably being phenyl, aryl being connected to R12 as defined in the following. Between said aryl sulfonamide and R12 further moieties may be present, said further moieties preferably being isosteric with the corresponding moieties of the particularly preferred group binding between subunits 131 and 132 as disclosed in the following. Particuarly preferred is that said group binding between subunits 131 and 132 is 442-(4-R12-oxy-phenyl) quinolin-4-y1 carboxamido] benzene N-acetyl sulfonamide. R12 is a linker connecting said group binding between subunits 131 and 132 to X, preferably being C5 to C10 alkyl, C5 to C10 alkenyl or ¨[0-(CH2)2]1-5, wherein one or more C atoms in said linker may be replaced with 0 and/or N.
Said alkenyl group may comprise one, two or more double bonds.
So far, the group Y¨Z has been displayed as a double bond, wherein one of the two bonds comprised in the double bond is dashed. This indicates that Y and Z may either be connected by a double bond or a single bond.
In a preferred embodiment, Y¨Z is Y=Z, and preferably selected from CH=0 or CH=CH2. In an alternative, Y¨Z is Y¨Z and is preferably selected from CH2-1, CH2-Br, CH2-CI, CH2-OPO(OH)2, CH2-0Ts or CO-NHS wherein OTs is p-toluene sulfonyloxy and NHS is N-oxy-succinimide. As an alternative to the NHS-activated ester, also other activated esters known in the art may be used.
In a further alternative preferred embodiment, Y¨Z is Y¨Z and preferably selected from 0-1, 0-Br, 0-CI, S-1, S-Br and S-I.
In a further preferred embodiment, R2 and R3 are identical and preferably methyl, H, methoxy or ¨CH2OH. Particularly preferred is that both R2 and R3 are methyl or that both R2 and R3 are H. Especially preferred is that both R2 and R3 are methyl.
Preferred is that X is CO.
Preferred is that Y¨Z is CH=0. Also preferred is that Y¨Z is CO-NHS.
Particularly preferred is that X is C=0 and Y¨Z is CH=0 or CO-NHS.
Particularly preferred is that X is C=0 and Y¨Z is CH=0 or CO-NHS and both R2 and R3 are methyl.
The following preferred embodiments are dedicated to preferred implementations of the targeting moiety R1. Any of the preferred embodiments of R1 can be combined with any of the preferred embodiments of X, Y, Z, R2 and R3.
In a preferred embodiment, said peptidic group consists of three a-amino acids, wherein preferably (a) the N-terminal amino acid is selected from Ser(OMe), Leu, Phe and Ala; the middle amino acid is selected from Ser(OMe), Leu, Phe and Ala; and/or the C-terminal amino acid is selected from Phe, Tyr, Leu, Ser(OMe) and Ala; or (b) said peptidic group consists of Ser(OMe)-Ser(OMe)-Phe, Leu-Leu-Tyr or Ala-Ala-Ala.
Said N-terminal amino acid is also referred to as the moiety defining the S3 site of the inhibitor. Said middle amino acid defines the S2 site. Said C-terminal amino acid defines the S1 site.
In a further preferred embodiment, said group enhancing delivery is present and is R11-00, !I .-01 -CS-, or R11-S02-, R11 being selected from the following substituted or unsubstituted groups, groups being carbocyclyl, heterocarbocyclyl, carbocyclyl alkyl, heterocarbocyclyl alkyl, alkyl heterocarbocyclyl alkoxy heterocarbocyclyl, alkoxyalkyl heterocarbocyclyl, heterocarbocyclyl amino, heterocarbocyclyl alkyl heterocarbocyclyl, and alkyl heterocarbocyclyl alkyl heterocarbocyclyl, wherein alkyl is C1 to C4 alkyl, preferably methyl, substituents are C1 to C4 alkyl, preferably methyl or ethyl, C1 to C4 alkoxy, preferably methoxy or ethoxy, hydroxy and/or halogen, preferably Cl, Br or I, and heteroatoms are 0, N and/or S.
R11-CO is particularly preferred.
R11 being heterocarbocyclyl is particularly preferred.
The term "carbocyclyl" designates a ring molecule, wherein the ring comprises carbon atoms.
The ring may be formed exclusively by carbon atoms, but does not have to.
Accordingly, one, two or more heteroatoms may be present. The ring may be saturated in which case it would be a cyclic alkane, optionally comprising one or more heteroatoms. The ring may contain one, two or more double bonds. If said double bonds are conjugated, carbocyclyl is an aryl moiety.
In a particularly preferred embodiment, (a) said carbocyclyl is aryl or biaryl, aryl being monocyclic or bicyclic and preferably phenyl or naphthyl; and (b) said heterocarbocyclyl is heteroaryl, heteroaryl being monocyclic or bicyclic, bi-heteroaryl, aryl heteroaryl, heteroaryl aryl or heterocycloalkyl, heteroaryl preferably being furyl, thienyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, pyridinyl, pyrazinyl, pyridazinyl or quinolinyl, aryl preferably being phenyl, heterocycloalkyl preferably being morpholinyl or tetrahydrofuranyl.
Particularly preferred is that heterocarbocyclyl is heteroaryl, in particular monocyclic heteroaryl.
In a particularly preferred embodiment R11 is selected from 2-methyl thiazol-5-y1; 4-morpholinyl methyl; 1,4-dichloro 2-phenyl; 6-phenylpyridin-2-y1; pyrazin-2-y1;
3-furyl; 2-thienyl;
5-oxazoly1; 5-isoxazoly1; (5-Me)-3-isoxazoly1; (5-iPr)-3-isoxazoly1; (5-MeOCH2)-3-isoxazoly1;
3-pyrazoly1; 2-imidazoly1; (N-Me)-3-pyrazoly1; (N-Me)-2-imidazoly1; (5-Me)-3-pyrazoly1; 4-pyridinyl; 4-pyridazinyl; 2-(R)-tetrahydrofuranyl; 2-(S)-tetrahydrofuranyl; (5-Me)-3-isoxazolyl-NH-; pyrazin-2-y1; naphth-2-y1; quinolin-2-y1; 4-biphenyl; 3-biphenyl; 4-phenylpyridin-2-y1; 3-phenyl-pyridin-2-y1; 5-phenylpyrazin-2-y1; 6-phenylpyrazin-2-y1; 2-phenyl-thiazol-4-y1; and 5-R111-isoxazol-3-y1;
wherein RII' is selected from methyl, 4-morpholinyl methyl, 1,2,4-triazoly1 methyl, imidazolyl methyl and N-methyl piperazinyl methyl.
Especially preferred is that R11 is 2-methyl thiazol-5-yl.
Especially preferred compounds of the first aspect are the compounds of formulae (11a) and (11b):
R
R 1 ).HO
(11a) (11b), wherein R1 is R11-CO-Ser(OMe)-Ser(OMe)-NH-CH(CH2-C6H5), R11 being as defined above, and wherein most preferably R1 is 2-methyl thiazol-5-y1 carbonyl Ser(OMe)-Ser(OMe)-NH-CH(CH2-C6H5).
In a second aspect, the present invention provides the use of a compound as defined in the first aspect as a proteasome inhibitor.
One or a plurality of compounds in accordance with the first aspect may be used.
Preferably, said proteasome is a proteasome core particle (CP) which is also known as 20S
proteasome. In a preferred embodiment, the constitutive core particle (cCP) is used.
Alternatively, tissue-specific proteasomal subtypes such as immunoproteasome (iCP) or the thymusproteasome (tCP) may be used.
A proteasome inhibitor in accordance with the present invention is a compound which inhibits one or more proteolytic activities of a proteasome. A proteasome comprises a plurality of proteolytic sites. Preferably, said proteolytic sites are as follows: a site with caspase-like proteolytic activity, a site with trypsin-like proteolytic activity and a site with chymotrypsin-like proteolytic activity. Proteasome inhibitors in accordance with the present invention are capable of inhibiting at least one of these sites. Preferred are compounds which are capable of inhibiting two or all three of these sites.
Related thereto, the present invention provides, in a third aspect, a method of inhibiting a proteasome, said method comprising bringing into contact a proteasome and a compound as defined in the first aspect, provided that methods for treatment of the human or animal body by therapy and diagnostic methods practised on the human or animal body are excluded and/or said method is performed in vitro or ex vivo.
Also provided is a method of inhibiting a proteasome, said method comprising bringing into contact a proteasome and a compound as defined in the first aspect. The method may be performed in vivo.
It is understood that said bringing into contact is effected under conditions which allow a physical contact between said compound and the proteasome. Suitable conditions include aqueous solutions, such as buffered aqueous solutions. Exemplary conditions can be found in the examples enclosed herewith.
The examples include also a proteasome activity assays in accordance with the invention.
A preferred proteasome activity assay is as follows. The activity assay is based on the cleavage of 7-amino-4-methyl-coumarin (AMC) substrates consisting of the fluorophore AMC
fused N-terminal to a peptide backbone. These substrates are fluorogenic as the cleaved AMC exhibits fluorescence (emission wavelength: 380 nm; emission wavelength:
460 nm).
For every active site a specific substrate is used (LLVY-AMC for the chymotryptic-like site, LLE-AMC for the caspase-like site, and RLR-AMC for the tryptic-like site).
Proteasome activity is monitored by first mixing inhibitor and substrate simultaneously in assay buffer and incubation for 3 min at 37C . After the addition of 50 nM proteasome and mixing, the increase in fluorescence (excitation wavelength: 380 nm; emission wavelength:
460 nm) is monitored with a spectrofluorimeter. DMSO concentration is kept for all measurements.
The fluorescence readout correlates with proteasome activity. This procedure is utilized to determine the first-order rate constant of inhibition. The IC50, which refers to the inhibitor concentration needed to decrease enzyme activity by 50%, can be determined by measuring proteasome activity at varying inhibitor concentrations.
In a fourth aspect, the present invention provides a medicament or lead compound for developing a medicament comprising or consisting of a compound as defined in the first aspect.
The terms "medicament" and "pharmaceutical composition" are used equivalently herein. A
pharmaceutical composition in accordance with the present invention may comprise a pharmaceutically acceptable carrier, diluent or excipient.
Examples of suitable pharmaceutically acceptable carriers, excipients and/or diluents are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods.
These pharmaceutical compositions can be administered to the subject at a suitable dose.
Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration. It is particularly preferred that said administration is carried out by injection. The compositions may also be administered directly to the target site, e.g., by biolistic delivery to an external or internal target site. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
Pharmaceutically active matter may be present in amounts between 1 ng and 10 mg/kg body weight per dose;
however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. If the regimen is a continuous infusion, it should also be in the range of 1 pg to 10 mg units per kilogram of body weight per minute. Preferred doses are in the range from about 10 to about 40 mg/m2 body surface, which correspond to about 0.25 to about 1 mg/kg body weight.
One or more compounds in accordance with the first aspect of the present invention may be the only pharmaceutically active agent(s) comprised in a medicament in accordance with the present invention. Alternatively, one, two or more further pharmaceutically active agents may be present. Said further pharmaceutically active agents are preferably selected from known proteasome inhibitors and/or therapeutic agents for the treatment of multiple myeloma.
Known proteasome inhibitors are discussed above and include bortezomib, carfilzomib, ixazomib, marizomib, oprozomib, delanzomib, epoxomicin, dihydroeponemycin.
Exemplary agents for the treatment of multiple myeloma are lenalidomide and dexamethasone as well as the combination of the latter two.
The development of a lead compound into a medicament is also known as lead optimization.
Methods for the optimization of the pharmacological properties of lead compounds are known in the art and comprise a method of modifying a lead compound to achieve: (i) modified site of action, spectrum of activity, organ specificity, and/or (ii) improved potency, and/or (iii) decreased toxicity (improved therapeutic index), and/or (iv) decreased side effects, and/or (v) modified onset of therapeutic action, duration of effect, and/or (vi) modified pharmacokinetic parameters (resorption, distribution, metabolism and excretion), and/or (vii) modified physico-chemical parameters (solubility, hygroscopicity, color, taste, odor, stability, state), and/or (viii) improved general specificity, organ/tissue specificity, and/or (ix) optimized application form and route by (i) esterification of carboxyl groups, or (ii) esterification of hydroxyl groups with carboxylic acids, or (iii) esterification of hydroxyl groups to, e.g.
phosphates, pyrophosphates or sulfates or hemi-succinates, or (iv) formation of pharmaceutically acceptable salts, or (v) formation of pharmaceutically acceptable complexes, or (vi) synthesis of pharmacologically active polymers, or (vii) introduction of hydrophilic moieties, or (viii) introduction/exchange of substituents on aromates or side chains, change of substituent pattern, or (ix) modification by introduction of isosteric or bioisosteric moieties, or (x) synthesis of homologous compounds, or (xi) introduction of branched side chains, or (xii) conversion of alkyl substituents to cyclic analogues, or (xiii) derivatisation of hydroxyl group to ketales, acetales, or (xiv) N-acetylation to amides, phenylcarbamates, or (xv) synthesis of Mannich bases, imines, or (xvi) transformation of ketones or aldehydes to Schiff's bases, oximes, acetales, ketales, enolesters, oxazolidines, .. thiazolidines or combinations thereof.
The various steps recited above are generally known in the art. They include or rely on quantitative structure-action relationship (QSAR) analyses (Kubinyi, "Hausch-Analysis and Related Approaches", VCH Verlag, Weinheim, 1992), combinatorial biochemistry, classical chemistry and others (see, for example, Holzgrabe and Bechtold, Deutsche Apotheker Zeitung 140(8), 813-823, 2000).
In a fifth aspect, the present invention provides a compound as defined in the first aspect for use in a method of treating, ameliorating or preventing cancer, an autoimmune disease, muscular dystrophy, emphysema, or cachexia accompanying cancer or AIDS.
More generally speaking, the compounds in accordance with the invention are useful in methods of treating, ameliorating or preventing any condition which is amenable to treatment, prevention or amelioration via inhibition of a proteasome.
In a preferred embodiment, said cancer is a lymphoid malignancy, preferably selected from multiple myeloma (MM) including relapsed and refractory MM; non-Hodgkin lymphoma such as B-cell lymphomas including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), and Waldenstrom macroglobulinaemia.
In a further preferred embodiment said autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, Sjorgen's syndrome or scleroderma.
In a sixth aspect, the present invention provides a method of identifying a compound capable of inhibiting a proteasome, said method comprising bringing into contact a test compound of formula (III) X -(III), wherein R4 is an organic group, and X, Y, Z, R2 and R3 are as defined in accordance with the first aspect or preferred embodiments thereof, with a proteasome, wherein a decreased activity of the proteasome in presence of said test compound as compared to the absence thereof is indicative of said test compound being a compound capable of inhibiting a proteasome.
This aspect relates to a screening method. Screening may be a biochemical screen or a cellular screen. Generally speaking, a variety of assay designs are available for the purpose of identifying compounds which are capable of inhibiting the activity of a given target molecule, here a proteasome. One of the established distinctions is between cellular assays and biochemical assays. Cellular assays are sometimes viewed as mimicking closer the in vivo situation, however, they suffer from the drawback that any candidate compound generally has to pass the cell membrane in a first step. Biochemical assays are simpler in that respect. The target, here a proteasome, may be presented in enriched or purified form in aqueous solution. In such an assay scenario there is no membrane barrier. The conditions, though, may be further remote from the environment in the organism to be subjected to therapy.
A negative control for the screen is the absence of any test compound as disclosed above.
As positive controls one or more compounds in accordance with the first aspect or known proteasome inhibitors as disclosed herein may be used.
As known in the art, screening methods may be implemented in a high throughput fashion.
Accordingly, said method may be effect in a high throughput format. High throughput assays generally may be performed in wells of microtiter plates, wherein each plate may contain 96, 384 or 1,536 wells. Handling of the plates, including incubation at temperatures other than ambient temperature, and bringing into contact of these compounds with the assay mixture is preferably effected by one or more computer controlled robotic systems including pipetting devices. In case large libraries of test compounds are to be screened and/or screening is to be effected within short time, mixture of, for example 10, 20, 30, 40, 50 or 100 test compounds may be added to each well. In case a well exhibits biological activity, in the present case inhibition of a proteasome, said mixture of test compounds may be de-convoluted to identify one or more test compounds in said mixture giving rise to said activity.
A compound capable of inhibiting a proteasome is also referred to as proteasome inhibitor.
Inhibition preferably amounts a decrease of activity of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%.
Further preferred is a 102-fold, 103-fold, 104-fold, 105-fold, 108-fold, 107-fold, 108-fold or 109-fold reduction of activity.
An art-established measure of inhibitory activity is the IC50 value which is the inhibitor concentration where 50% inhibition occurs. Preferably, proteasome inhibitors to be identified by the method of identifying of the present invention as well as compounds in accordance with the first aspect exhibit IC50 values in the one digit pM range, preferably below 1 pM, more preferably below 100 nM, below 10 nM, below 1 nM, or below 100 pM. IC50 values are preferably determined using the proteasome activity assay as described above.
In accordance with the method of the sixth aspect, R4 is not particularly limited. In fact, one of the applications of this method is the identification of further targeting moieties which targeting moieties may be different from the targeting moieties defined in relation to the first aspect of the invention.
As noted above, R4 is an organic group. It may have a molecular weight between 200 and 1,000 Da.
In a preferred embodiment, said activity is a proteolytic activity, preferably selected from caspase-like, trypsin-like and chymotrypsin-like activity.
In a further preferred embodiment said proteasome is comprised in an in vitro or ex vivo cell.
This preferred embodiment refers to a cellular assay.
A preferred cellular assay is as follows. Cells (e.g. HEK 293) are transfected with the pZsProSensor-1 vector (Clontech Laboratories, Inc.), a reporter gene construct for proteasomal activity. This vector encodes for a destabilized green fluorescent protein variant (ZsGreen) fused C-terminally to a specific degradation motif mediating the recognition and degradation by the proteasome. The fluorescence readout (excitation wavelength: 493 nm;
emission wavelength: 505 nm) of expressed ZsGreen is used to monitor proteasome activity.
Inhibition of the proteasome causes accumulation of ZsGreen correlating with an increased fluorescence signal in the GFP channel.
In a seventh aspect, the present invention provides a compound of formula (IV) X
Z
(IV), wherein A is selected from NH-NH2, N3 and a click chemistry functional group;
X, Y, Z, R2 and R3 are as defined above.
In an eighth aspect, the present invention provides the use of a compound of formula (IV) X
Z
(IV), wherein A is selected from NH-N H2, N3 and a click chemistry functional group;
X, Y, Z, R2 and R3 are as defined above;
in the synthesis of a proteasome inhibitor, of a pharmaceutically active agent or of a lead compound for the development of a pharmaceutically active agent, said pharmaceutically active agent preferably being for use in a method of treating or preventing cancer or an autoimmune disease.
The latter two aspects of the invention are directed to the headgroup or warhead of proteasome inhibitors in accordance with the present invention.
Generally speaking, A is a reactive group. Art-established reactive groups may be used. The purpose of A is to provide robust irreversible coupling to targeting moieties such as R1 as defined above. The reactive group A may be used for coupling to any targeting moiety. Upon coupling to a targeting moiety, compounds in accordance with the first aspect may be obtained.
"Click-chemistry is an art-established term; see e.g. Kolb et al. (2001) Click chemistry:
diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40
(11):2004;
Sletten et al. (2009) Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality.
Angew. Chem. Int. Ed.48:6998; Jewett et al.(2010) Cu-free click cycloaddition reactions in chemical biology. Chem. Soc. Rev. 39(4):1272; Best et al. (2009) Click Chemistry and Bioorthogonal Reactions: Unprecedented Selectivity in the Labeling of Biological Molecules.
Biochemistry.48:6571; and Lallana et al. (2011) Reliable and Efficient Procedures for the Conjugation of Biomolecules through Huisgen Azide¨Alkyne Cycloadditions.
Angew. Chem.
Int. Ed. 50:8794.
As regards the embodiments characterized in this specification, in particular in the claims, it is intended that each embodiment mentioned in a dependent claim is combined with each embodiment of each claim (independent or dependent) said dependent claim depends from.
For example, in case of an independent claim 1 reciting 3 alternatives A, B
and C, a dependent claim 2 reciting 3 alternatives D, E and F and a claim 3 depending from claims 1 and 2 and reciting 3 alternatives G, H and I, it is to be understood that the specification unambiguously discloses embodiments corresponding to combinations A, D, G; A, D, H; A, D, I; A, E, G; A, E, H; A, E, I; A, F, G; A, F, H; A, F, I; B, D, G; B, D, H;
B, D, I; B, E, G; B, E, H; B, E, I; B, F, G; B, F, H; B, F, I; C, D, G; C, D, H; C, D, I; C, E, G; C, E, H; C, E, I; C, F, G;
C, F, H; C, F, I, unless specifically mentioned otherwise.
Similarly, and also in those cases where independent and/or dependent claims do not recite alternatives, it is understood that if dependent claims refer back to a plurality of preceding claims, any combination of subject-matter covered thereby is considered to be explicitly disclosed. For example, in case of an independent claim 1, a dependent claim 2 referring back to claim 1, and a dependent claim 3 referring back to both claims 2 and 1, it follows that the combination of the subject-matter of claims 3 and 1 is clearly and unambiguously disclosed as is the combination of the subject-matter of claims 3, 2 and 1. In case a further dependent claim 4 is present which refers to any one of claims 1 to 3, it follows that the combination of the subject-matter of claims 4 and 1, of claims 4, 2 and 1, of claims 4, 3 and 1, as well as of claims 4, 3, 2 and 1 is clearly and unambiguously disclosed.
The figures show:
Figure 1: Chemical structures of representative members of the epoxyketone class of proteasome inhibitors. Shown are the natural products epoxomicin (top right) and dihydroeponemycin (bottom right), which were isolated from bacterial strains.
Also depicted are synthetic derivative of the parent natural product molecules. Carfilzomib (top left) was recently approved for the treatement of multiple myeloma and is currently in clinical trials for the treatment of other cancers. Oprozomib is currently in clinical trials as an orally available multi-potent inhibitor for the treatment of several cancers.
Figure 2: Crystal structures of co-crystal structures of human 20S proteasomes in complex .. with epoxyketone inhibitors. 2Fo-Fc electron density maps are shown contoured at 1.5 a for the proteasome active site inhibited with carfilzomib (top left), oprozomib (bottom left), epoxomicin (top right) and dihydroeponemycin (bottom right). Note that the electron density map reveals density for an additional carbon atom. In all cases, the modeled cyclic ring structure is consistent with a 1,4-oxazepane structure formed by the reaction of epoxyketone inhibitors with the active site catalytic threonine side chain.
Figure 3: Confirmation that a 7-membered 1,4-oxazepane ring structure is formed upon inhibition of proteasomes with epoxyketone inhibitors. Shown are the chemical structures of Oprozomib (top left) and dihydroeponemycin (top right). The oval highlights that Oprozomib contains a methyl group and dihydroeponemycin a methanolic group in the carbon atom in a-position to the ketone, respectively. The bottom panels illustrate the 135 active site inhibited with Oprozomib (bottom left) and Dihydroeponemycin (bottom right), along with an omit map contoured at 4a for the inhibitor, the cyclic linkage and 135Thr2. The main chain segments of 135 residues 2, 19-21, 33, 45-50, 129-131, 169,170 and 136 125,126 are indicated along with the 135 side chains of Thr2, Thr23, Lys33, Ser130 and the side chains of 136 Asp125, Pro126 as sticks. Dashed lines signify hydrogen bonds 3.2 A distance). In the respective bottom right panels close-up views of the inhibitor-Thr1 linkages are shown along with an omit map contoured at 6a. Note that the electron density map does not support a chiral center in the case of epoxomicin, which contains a methyl and a methanolic group, which would be a consequence of the proposed mechanism for 1,4-morpholine ring formation (bottom left) (Groll et al., /oc. cit.). The dihydroeponemycin structure does not reveal electron density consistent with the presence of two methanolic groups, yet again disproving 1,4-morpholine ring formation (bottom right).
Figure 4: Attempts to model a 1,4-morpholine ring structure in the linkage occurring between epoxyketone inhibitor and the proteasome active site Threonine1. Shown is an overlay of the proteasome active site (main chain) inhibited by a 1,4-oxazepane linkage and the attempted 1,4-morpholine linkage. The attempted 1,4-morpholine refinement reveals that a van-der-Waals clash occurs with the methyl group of the inhibitor and the main chain carbonyl atoms of R19 and Y169. Additionally, strong negative difference density at 5 sigma is visible at the C5 methanol atom of the 1,4-morpholine linkage. Positive densities are visible at positions 4 and 5 of the 1,4-oxazepane linkage. These findings entirely exclude formation of 1,4-morpholine ring formation in the epoxyketone inhibited proteasome active site.
Figure 5: Enzymatic characterization of proteasome catalytic activity.
Measurements were performed as described in methods. The left panel depicts a typical kinetic experiment, where the increase in fluorescence signal of the AMC released by proteolytic cleavage is plotted against time. The left window signifies an activation phase in enzymatic peptide cleavage, whereas the right window represents the steady-state phase. In the right panel the specific activities for the human 20S proteasome purified by our method are indicated for the pre-steady-state (prior to activation) or and the steady-state phases, respectively. The equation shown in the right panel was used to perform fits against the experimental data. Fo designates the initial fluorescence, AFss: fluorescence increase in the steady-state part of the measurement, kact: the rate constant. The exponential term with the rate constant kact is used to describe the activation phase of the reaction.
The examples illustrate the invention.
Example 1 Crystallography Initial phases for human 20S proteasomes were determined by molecular replacement using the murine 20S structure (PDB ID: 3UNE). The model was then optimized by several rounds of interactive manual model building in Coot and refinement in Refmac5. The obtained structures display excellent stereochemistry with typical values for Rwork=
18% and Rfree=
21%, reveal superb electron densities for all 6724 residues and reveal several ligands as present in buffers used for purification and crystallization.
Using a dataset to 1.8 A resolution, we created a reference model. With the availability of this excellent model for the human 20S proteasome, now structure determination takes minutes by automated refinement of the reference model against integrated and scaled X-ray data from related crystals. Bound ligands can then be rapidly identified in difference density maps and modeled interactively in Coot.
Native crystals were soaked with the epoxyketone inhibitors shown in Figure 1.
Co-crystal structures of human 20S proteasomes in complex with these inhibitors at resolutions between 1.9 ¨ 2.1 A (0.3-0.5 A better resolution than presently available structures) were solved. Surprisingly, after refinement of these co-crystal structures, which allow the modelling of all parts of human 20S proteasomes at atomic resolution, it was not possible to visualize the presumed 1,4-morpholine ring structure in the inhibited state. The electron density maps in the new epoxyketone/human 20S proteasome co-crystal structures in all cases did not agree with the formation of a 1,4-morpholine 6-ring. Instead, density for an additional atom became clearly visible, which is consistent with a 7-ring structure. In fact, modelling the cyclic molecule visible in the inhibited state formed by the reaction of the epoxyketone inhibitors with the active site catalytic threonine amino acid revealed that it represents a 1,4-oxazepane 7-ring structure (Figure 2).
The observation of a 1,4-oxazepane structure contrasts with previously presumed chemical inhibition mechanisms of 20S proteasomes by epoxyketones. Therefore, a control experiment was performed to ensure that the observation of this 7-membered ring structure is true and the modelling of the 1,4-oxazepane structure in the inhibited proteasome active site is justified. Additionally, this control experiment should provide insight into the chemical inhibition mechanism by which the 7-ring structure is formed upon proteasome inhibition. For this control experiment, the co-crystal structures determined using the epoxyketone inhibitors epoxomicin and dihydroeponemycin were compared. Epoxomicin contains an epoxide group with a methyl ligand at the carbon atom, where the nucleophilic attack is presumed to occur in order to form the presumed 1,4-morpholine inhibited ring structure (Figure 3, top left).
Additionally, after formation of the presumed 1,4- morpholine structure ring opening of the epoxide at the carbon atom in a-position to the ketone should yield a stereo center, which contains both a methyl and a methanolic group (Figure 3, right panel) (Groll et al., /oc. cit.).
Dihydroeponemycin in contrast already contains a methanolic ligand at the carbon atom, where the nucleophilic attack is presumed to occur in order to form the proposed 1,4-morpholine inhibited ring structure (Figure 3, top right). As a consequence, after formation of the proposed 1,4-morpholine structure ring opening of the epoxide at the carbon atom in a-position to the ketone should yield a non-chiral center, which contains two methanolic groups. At the resolutions at which both co-crystal structures were determined (1.9 and 2.0 A), it is possible to verify if this is the case. Surprisingly however, the electron density maps of both structures revealed that the inhibited state is formed by the covalent attack of the electrophilic carbon atom in 13-position to the ketone (Figure 3, bottom panels), excluding the possibility that a 1,4-morpholine ring structure is formed in the inhibited state by the absence of electron density compatible with a methanolic group in the case of epoxomicin and two methanolic groups in dihydroeponemycin.
Attempts to model the electron density in the active site of the dihydroeponemycin complex by a 1,4-morpholine ring structure linkage were unsuccessful (Figure 4). 1,4-morpholine linkage refinement resulted in a severely distorted molecular geometry characterized by the elongation of the N4-carbon bonds by 0.1-0.2 A, shortening of the C5-alcohol carbon bond by 0.1 A and deviation of the methyl-05-alcohol bond angle by -20 degrees off the expected value. Additionally, the methyl carbon exhibited a van-der-Waals distance of 3.0 A to the Arginine 19 and Tyrosine 169 main chain oxygen atoms, which is too close.
Moreover, strong negative difference density peaks in difference maps contoured at 5 sigma levels at the C5 , methanol oxygen of the 1,4-morpholine ring model, as well as positive density peaks contoured at 4.5 sigma levels close to positions 4 and 5 of our 1,4-oxazepane ring model remained after this 1,4-morpholine ring refinement. In contrast, no residual difference (neither negative nor positive) density was present in the refined 1,4-oxazepane linkage in density maps contoured above 2.3 sigma.
Example 2 Synthesis , , , .
, >QLOel HN OH ____ 1. EDC, DMAP, 9--0)FIN 0 * Mel, --)----di'L FIN
0 *
(1) 0 MeIdrum acid o 0 K2CO3 o 0 2.BnOH (2) (3) .
, TEA, ' CH2Cl2 .
, o o o 0 H H
\ AN
, _____________________________________________________________ H2N
NJL 0 , ___________ N 0 a HOBt N 0 -,.., 0 Methal101 N 0 -, 0 EDC, o o (6) ? (5) ?
peptide (18) (4) N-Hydroy- i.
succinimide, EDC
µ' I
0 o syt,) jy Li li o,IA
---i 1 11 ---:--"-N
r H
(7) ?
Scheme 3: Synthesis of NHS-ester. Details are given below; see steps A to F.
0 0,c,"' ' 1 _ 1 il 9'-'051'HN __ OH
MeNHOMe, Ha ...)---01HN N' __________ o 0 NEt3, BOB, CH2Cl2 o i o 0-(1) (8) (8) (9-1) ITFA, CH2Cl2 0 i o o o o fyi jc) N t, 1, ./
____eyLEXNHAN ,0 , 0\
MeCOH, /YL HI N N 0 \ EH (1::: II H
, H r H
Isl- 0 ,-.7 0 p-TSOH
,___,s o -,..., 7 (12) (11) ? peptide (18) (10) Scheme 4: Synthsesis of p-keto aldehyde. Details are given below; see steps G
to K.
, , , , , >L0j1,) N,c0H >LoiNfy0 ___________ fy0 T, DMAP, TFA, CH2Cl2 H2NEA HOBt/HBTU, o Benzyl chloro- 0 0 DIEA 0 (13) formate (14) (15) peptide (13) (16) TFA, CH2Cl2 OH
NifrN--- -0 H2NNOio 0 7,0 H2, Pd/C, o HOBt/HBTU, 0 (19) (18) Methanol DIEA (17) I ?
Nrq co2H
Scheme 5: Synthesis of tripeptide. Details are given below; see steps L to Q.
A) To a solution of N-Boc-L-Phenylalanine (1) in CH2Cl2 is added a EDC (1 eq.), DMAP (1 eq.) and Meldrum's acid (1 eq.). The reaction is stirred at room temperature for 17 hours, then poured into 1 M HCl. The layers are separated and the aqueous layer is extracted three times with CH2Cl2. The organic layers are combined, washed with brine, dried over MgSO4 and concentrated in vacuum. The residue is heated to 80 C in toluene and after the addition of benzyl alcohol (1 eq.) for 4 hours. The solvent is the removed in vacuum and the residue purified by flash chromatography and elution with ethyl acetate to yield (2).
B) A solution of (2), methyl iodide (3 eq.) and potassium carbonate (2 eq.) in acetone is heated under reflux for 17 hours. 2 volume equivalents of water are added and the resulting mixture extracted three times with 2 volume equivalents ethyl acetate. The organics are combined, dried over MgSO4 and concentrated in vacuum. The residue is purified by preparative HPLC in 0.1 % formic acid in water, with a gradient to 0.1 %
formic acid in acetonitrile to give (3).
C) A solution of (3) is stirred in a 10 % TFA solution in CH2Cl2 for 17 hours at room temperature. The solvent is subsequently removed in vacuum to yield (4).
D) To (4) (1 eq.) in CH2Cl2 and triethylamine (0.001 eq.) is added (19) (1 eq.), HOBT (0.2 eq.) and EDC (2 eq.). The solution is stirred at 25 C for 24 hours and then washed three times with saturated sodium hydrogencarbonate solution, once with deionized water and brine each, and the organic layer is dried over MgSO4. The solvent is removed in vacuum and the residue purified by flash chromatography eluting with 1:1 ethyl acetate:n-hexane to yield (5).
E) (5) is stirred in methanol containing 10% Pd/C under a hydrogen atmosphere (1 atm).
After 2 hours the mixture is filtered through celite and the solvent removed in vacuo to the product (6).
F) To (6) in CH2Cl2 is added, EDC (2 eq.) and N-Hydroxysuccinimide (2 eq.) and the mixture stirred for 2 hours. The solvent is then removed in vacuo and the residue purified by flash chromatography, eluting with 1:5 ethyl acetate:n-hexane to yield (7).
G) To a stirred solution of Boc-L-Phenylalanine in CH2C12 is added 0,N-dimethylhydroxylamine hydrochloride (1 eq.), triethylamien (2 eq.) and BOP (1 eq.). After 3.5 hours the solution is diluted 4-fold with CH2C12 and washed three times with 3 M HCL, three times with saturated sodium hydrogencarbonate and three times with brine. The organic layer is then dried over MgSO4, the solvent removed in vacuo and the residue purified by flash chromatography with 1:3 ethyl acetate:n-hexane to yield (8).
H) The Weinreb amide (8) in THF under an Argon atmosphere is cooled to 0 C
and 1,3-Dioxacyclopenty1-2-MgBromide (5 eq.) in THF added dropwise. The reaction is allowed to reach 25 C and after 4 hours of stirring, is quenched with 1 M HCl forming a precipitate. The precipitate is removed by filtration and washed three times with ethyl acetate. The combined organics are then washed with brine, dried over MgSO4 and the solvent removed in vacuum.
The residue is then purified by flash chromatography using 1:4 ethyl acetate:
n-hexane as an eluent to yield (9).
1) A solution of (9) is stirred in a 10 % TFA solution in CH2C12 for 17 hours at room temperature. The solvent is subsequently removed in vacuum to yield (10).
J) To (10) (1 eq.) in CH2C12 and triethylamine (0.001 eq.) is added (19) (1 eq.), HOBT (0.2 eq.) and EDC (2 eq.). The solution is stirred at 25 C for 24 hours and then washed three times with saturated sodium hydrogencarbonate solution, once with deionized water and brine each, and the organic layer is dried over MgSO4. The solvent is removed in vacuo and the residue purified by flash chromatography eluting with 1:1 ethyl acetate:n-hexane to yield (11).
K) A solution of (11) and p-Ts0H (0.1 eq.) in acetaldehyde (0.5 eq.) is stirred under an argon atmosphere at 15 C for 23 hours. The solvent is then removed in vacuum and the residue purified by flash chromatography, eluting with 1:5 ethyl acetate:n-hexane to yield (12).
L) To a solution of Boc-methylserine (13) in DCM (Dichlormethane) TEA
(Triethylamine) and DMAP (4-Dimethylaminopyridine) are added. The resulting solution is cooled to -5 C, and benzyl chloroformate is then slowly added via an addition funnel under an atmosphere of argon. The reaction is kept at the same temperature for 3 h and then diluted with brine. The layers are separated, and the aqueous layer is extracted with DCM. The organic layers are combined and dried over Na2SO4. The Na2SO4 is removed by filtration, and the volatiles are removed under reduced pressure. The resulting residue is purified by flash chromatography using a mixture of hexane and ethyl acetate to provide intermediate (14) as white solid.
M) To a 0 C solution of intermediate (14) in DCM TFA (Trifluoroacetic acid) is added slowly via a funnel. The reaction is kept at the same temperature for 1 h, concentrated, and dried under high vacuum overnight. The resulting residual TFA salt (15) is used in the next step without further purification.
N) To a -5 C mixture of aforementioned TFA salt (15), Boc-methylserine (13), HOBt (Hydroxybenzotriazole), and HBTU (2-(1H-benzotriazol-1-y1)-1,1,3,3-tetramethyluronium hexafluorophosphate) in THF (Tetrahydrofuran) (600 mL) is added DIEA slowly via an addition funnel. The reaction is kept at the same temperature for 4 h, followed by dilution with Et0Ac (Ethylacetate) and brine. The layers are separated, and the aqueous layer is extracted with Et0Ac (2 x 300 mL). The organic layers are combined and dried over Na2SO4. The Na2SO4 is removed by filtration, and the volatiles are removed under reduced pressure. The resulting residue is purified by flash chromatography using a mixture of hexane and ethyl acetate to provide dipeptide (16) as white solid.
0) To a 0 C solution of aforementioned intermediate (16) in DCM was added TFA
slowly via an addition funnel. The reaction is kept at the same temperature for 2 h, concentrated, and dried under high vacuum overnight. The resulting residual TFA salt (17) is used in the next step without further purification.
P) To a -5 C mixture of TFA salt (17), 2-methylthiazole-5- carboxylic acid, HOBt, and HBTU
in THF is added DIEA slowly. The reaction is kept at the same temperature for 4 h and then diluted with Et0Ac and brine. The layers are separated, and the aqueous layer is extracted with Et0Ac. The organic layers are combined and dried over Na2SO4. The Na2SO4 is removed by filtration, and the volatiles are removed under reduced pressure.
The resulting residue is purified by flash chromatography using a mixture of hexane and ethyl acetate to provide benzyl ester (18) as white solid.
Q) (18) is stirred in methanol containing 10% Pd/C under a hydrogen atmosphere (1 atm).
After 2 hours the mixture is filtered through celite and the solvent removed in vacuum to the product (19).
Example 3 Proteasome assays Activity measurement Preferred in vitro Assay.
All kinetic measurements were performed using a FluoroMax0-4 fluorescence spectrophotometer (Horiba Scientific). Succinyl-Leucine-Leucine-Valine-Tyrosine-7-amido-4-methylcoumarin (Suc-LLVY-AMC, Bachem) was used as substrate to determine the chymotryptic-like activity of the 135 catalytic active site of the human 20S
proteasome (R. L.
Stein, F. Melandri, L. Dick, Kinetic characterization of the chymotryptic activity of the 20S
proteasome. Biochemistry 35, 3899-3908 (1996)). The fluorescence emission of hydrolyzed AMC was continuously monitored at 460 nm (Aex = 380 nM). The reaction temperature was kept at 37 C for all measurements and the reaction buffer for enzymatic assays specified in Table S1 was used. Suc-LLVY-AMC and inhibitors (such as Oprozomib, Dihydroeponemycin, Z-LLY-Ketoaldehyde; "Sue" designating Succinyl and "Z"
designating Benzyloxycarbonyl) were dissolved in DMSO and stored at -80 C until usage.
The DMSO
concentration did not exceed 2% (v/v) in any measurement.For kinetic characterization of Suc-LLVY-AMC conversion, 0.035 mg/mL (50 nM) human 20S proteasome in reaction buffer was pre-incubated for 3 minutes at 37 C. The reaction was started by the addition of substrate and the fluorescence signal was measured continuously. For determination of the first-order rate constant of inhibition of the respective inhibitors, the reaction mixture containing reaction buffer, 150 pM substrate and either Oprozomib (50 pM), Dihydroeponemycin (50 pM) or Z-LLY-Ketoaldehyde (15 pM) were pre-incubated at 37 C for 3 minutes. The reaction was then started by the addition of human 20S
proteasome to a final concentration 50 nM. The fluorescence signal was measured continuously.
Data were analyzed and fitted with OriginPro 9.1 and KaleidaGraph 4.03. The equation shown in Figure 5 was used to analyze the chymotryptic-like catalytic activity and catalytic activation of the 20S proteasome. For the determination of the first-order inactivation rate constants, equations were used that contained either two exponential terms in case of Z-LLY-Ketoaldehyde, or two exponential terms plus a linear term for epoxyketones (Oprozomib and Dihydroeponemycin). The first of the two exponential terms accounts for the catalytic activation, whereas the second exponential term represents the catalytic inactivation by inhibitory action. The linear term in case of the epoxyketones was used to account for the residual activity of the proteasome after inactivation.
Alternative kinetic assay.
Time point measurements of the activity assays are performed to acquire an initial tendency of inhibitor binding. Different concentrations of 20S proteasome are used for each active site:
0.05 mg/ml for CL (Chymotryptic-like activity) and PGPH (Peptidyl-glutamyl peptide hydrolyzing activity) and 0.075 mg/ml for TL (Tryptic-like activity). The final reaction volume is 30 p1/well. A total number of five repetitions are performed to obtain root mean square deviation (RMSD), including a blank and a 100% initial activity reaction. The steps are as follows.
(1) A master mix is prepared: Respective amount proteasome (according to PGPH, TL, or CL
activity determination).
(2) Eppendorf tubes are prepared with the amount of the respective inhibitor to be analysed;
e.g. 500 pM concentration of the ligand in 30 pl is 1.5 pl per assay of a 10 mM inhibitor stock solution.
(3) 28.5 pl of the master mix is added to each Eppendorf tube. This solution is incubated for min at room temperature and transferred to the respective wells of the 96 well plates.
(4) Following incubation, 1 pl of a 7.5 mM stock solution of substrate for the caspase, 10 chymotryptic or tryptic site is added, giving a final substrate concentration of 250 pM. The plate is centrifuged and incubated at RT for 1 h.
(5) 300 pl of buffer is added to the reaction and the remaining proteasome activity is subsequently recorded by fluorescence at Ex (Excitation wavelength) 360 nm -Em (Emission wavelength) 460 nm.
15 (6) The remaining activity is calculated using the blank and 100%
initial activity.
Once proteasome inhibition is observed through the time point measurements, the half maximal inhibitory concentration (IC50) measurements can be performed. The percentage of the remaining activities is then plotted against the log concentration of the respective inhibitor. The obtained data are fitted with a conventional statistical program, for example as described in: Groll M, Gallastegui N, Marechal X, et al (2010) 20S Proteasome Inhibition:
Designing Non-Covalent Linear Peptide Mimics of the Natural Product TMC-95A.
ChemMedChem 5:1701-1705.
.. Reference for assay:
A description of an activity assay can be found in Gallastegui, N., & Groll, M. (2012).
Analysing Properties of Proteasome Inhibitors Using Kinetic and X-Ray Crystallographic Studies. In Methods in Molecular Biology (Vol. 832, pp. 373-390).
doi:10.1007/978-1-61779-474-2_26.
Cellular assays.
A further example is the Z-Sensor Proteasome assay from Takara/ Clontech.
ZsProSensor-1 is a proteasome-sensitive fluorescent reporter. It is a fusion of a bright green fluorescent protein (Exmax = 496 nm, Emmax = 506 nm) with a degradation domain which targets the protein for rapid degradation by the proteasome. The cells emit green fluorescence when there is a drop in proteasome activity.
Alternative methods:
Proteasome-GloTM Chymotrypsin-Like, Trypsin-Like and Caspase-Like Cell-Based Assays (Promega).
GFP-Assay: Bence N, Bennett E, Kopito R, Deshaies R. Application and analysis of the GFP(u) family of ubiquitin-proteasome system reporters. Ubiquitin and Protein Degradation, Pt B. 2005;399:481-490.
A cellular assay for the immunoproteasome is the following:
Fluorogenic in vitro assay (Immunoproteasome): (Basler, M., & Groettrup, M.
(2012).
Immunoproteasome-Specific Inhibitors and Their Application. In Methods in Molecular Biology (Vol. 832, pp. 391-401). doi:10.1007/978-1-61779-474-2_27) In order to test whether your IP inhibitor is cell permeable, the following method based on proteasome immuno- precipitation and in vitro activity assay can be used. The steps are as follows.
(1) Incubate cells for 2 h with desired concentration of IP inhibitors in cell culture media at 37 C. We normally use mouse splenocytes (one spleen per sample). As control, use an equal number of cells without inhibitor.
(2) Wash cells three times with PBS to remove unbound inhibitor.
(3) Lyse cells in 500 pl lysis buffer and incubate for 20 min on ice.
(4) Centrifuge the lysates for 10 min at 20,800 x g to remove debris.
(5) Discard pellet and add 3 pl of polyclonal rabbit-anti-mouse proteasome antibody and 50 pl protein A microbeads to the supernatant and incubate for 30 min on ice.
(6) Insert p column into magnet.
(7) Equilibrate p column with 1 ml NET-TON buffer.
(8) Load lysate on p column and discard flow through.
(9) Wash column twice with 1 ml NET-TON buffer and three times with NET-T
buffer.
.. (10) Add 50 pl of a fluorogenic substrate and incubate column for 30 min at 37 C.
(11) Add 200 pl lysis buffer and collect eluate.
Sletten et al. (2009) Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality.
Angew. Chem. Int. Ed.48:6998; Jewett et al.(2010) Cu-free click cycloaddition reactions in chemical biology. Chem. Soc. Rev. 39(4):1272; Best et al. (2009) Click Chemistry and Bioorthogonal Reactions: Unprecedented Selectivity in the Labeling of Biological Molecules.
Biochemistry.48:6571; and Lallana et al. (2011) Reliable and Efficient Procedures for the Conjugation of Biomolecules through Huisgen Azide¨Alkyne Cycloadditions.
Angew. Chem.
Int. Ed. 50:8794.
As regards the embodiments characterized in this specification, in particular in the claims, it is intended that each embodiment mentioned in a dependent claim is combined with each embodiment of each claim (independent or dependent) said dependent claim depends from.
For example, in case of an independent claim 1 reciting 3 alternatives A, B
and C, a dependent claim 2 reciting 3 alternatives D, E and F and a claim 3 depending from claims 1 and 2 and reciting 3 alternatives G, H and I, it is to be understood that the specification unambiguously discloses embodiments corresponding to combinations A, D, G; A, D, H; A, D, I; A, E, G; A, E, H; A, E, I; A, F, G; A, F, H; A, F, I; B, D, G; B, D, H;
B, D, I; B, E, G; B, E, H; B, E, I; B, F, G; B, F, H; B, F, I; C, D, G; C, D, H; C, D, I; C, E, G; C, E, H; C, E, I; C, F, G;
C, F, H; C, F, I, unless specifically mentioned otherwise.
Similarly, and also in those cases where independent and/or dependent claims do not recite alternatives, it is understood that if dependent claims refer back to a plurality of preceding claims, any combination of subject-matter covered thereby is considered to be explicitly disclosed. For example, in case of an independent claim 1, a dependent claim 2 referring back to claim 1, and a dependent claim 3 referring back to both claims 2 and 1, it follows that the combination of the subject-matter of claims 3 and 1 is clearly and unambiguously disclosed as is the combination of the subject-matter of claims 3, 2 and 1. In case a further dependent claim 4 is present which refers to any one of claims 1 to 3, it follows that the combination of the subject-matter of claims 4 and 1, of claims 4, 2 and 1, of claims 4, 3 and 1, as well as of claims 4, 3, 2 and 1 is clearly and unambiguously disclosed.
The figures show:
Figure 1: Chemical structures of representative members of the epoxyketone class of proteasome inhibitors. Shown are the natural products epoxomicin (top right) and dihydroeponemycin (bottom right), which were isolated from bacterial strains.
Also depicted are synthetic derivative of the parent natural product molecules. Carfilzomib (top left) was recently approved for the treatement of multiple myeloma and is currently in clinical trials for the treatment of other cancers. Oprozomib is currently in clinical trials as an orally available multi-potent inhibitor for the treatment of several cancers.
Figure 2: Crystal structures of co-crystal structures of human 20S proteasomes in complex .. with epoxyketone inhibitors. 2Fo-Fc electron density maps are shown contoured at 1.5 a for the proteasome active site inhibited with carfilzomib (top left), oprozomib (bottom left), epoxomicin (top right) and dihydroeponemycin (bottom right). Note that the electron density map reveals density for an additional carbon atom. In all cases, the modeled cyclic ring structure is consistent with a 1,4-oxazepane structure formed by the reaction of epoxyketone inhibitors with the active site catalytic threonine side chain.
Figure 3: Confirmation that a 7-membered 1,4-oxazepane ring structure is formed upon inhibition of proteasomes with epoxyketone inhibitors. Shown are the chemical structures of Oprozomib (top left) and dihydroeponemycin (top right). The oval highlights that Oprozomib contains a methyl group and dihydroeponemycin a methanolic group in the carbon atom in a-position to the ketone, respectively. The bottom panels illustrate the 135 active site inhibited with Oprozomib (bottom left) and Dihydroeponemycin (bottom right), along with an omit map contoured at 4a for the inhibitor, the cyclic linkage and 135Thr2. The main chain segments of 135 residues 2, 19-21, 33, 45-50, 129-131, 169,170 and 136 125,126 are indicated along with the 135 side chains of Thr2, Thr23, Lys33, Ser130 and the side chains of 136 Asp125, Pro126 as sticks. Dashed lines signify hydrogen bonds 3.2 A distance). In the respective bottom right panels close-up views of the inhibitor-Thr1 linkages are shown along with an omit map contoured at 6a. Note that the electron density map does not support a chiral center in the case of epoxomicin, which contains a methyl and a methanolic group, which would be a consequence of the proposed mechanism for 1,4-morpholine ring formation (bottom left) (Groll et al., /oc. cit.). The dihydroeponemycin structure does not reveal electron density consistent with the presence of two methanolic groups, yet again disproving 1,4-morpholine ring formation (bottom right).
Figure 4: Attempts to model a 1,4-morpholine ring structure in the linkage occurring between epoxyketone inhibitor and the proteasome active site Threonine1. Shown is an overlay of the proteasome active site (main chain) inhibited by a 1,4-oxazepane linkage and the attempted 1,4-morpholine linkage. The attempted 1,4-morpholine refinement reveals that a van-der-Waals clash occurs with the methyl group of the inhibitor and the main chain carbonyl atoms of R19 and Y169. Additionally, strong negative difference density at 5 sigma is visible at the C5 methanol atom of the 1,4-morpholine linkage. Positive densities are visible at positions 4 and 5 of the 1,4-oxazepane linkage. These findings entirely exclude formation of 1,4-morpholine ring formation in the epoxyketone inhibited proteasome active site.
Figure 5: Enzymatic characterization of proteasome catalytic activity.
Measurements were performed as described in methods. The left panel depicts a typical kinetic experiment, where the increase in fluorescence signal of the AMC released by proteolytic cleavage is plotted against time. The left window signifies an activation phase in enzymatic peptide cleavage, whereas the right window represents the steady-state phase. In the right panel the specific activities for the human 20S proteasome purified by our method are indicated for the pre-steady-state (prior to activation) or and the steady-state phases, respectively. The equation shown in the right panel was used to perform fits against the experimental data. Fo designates the initial fluorescence, AFss: fluorescence increase in the steady-state part of the measurement, kact: the rate constant. The exponential term with the rate constant kact is used to describe the activation phase of the reaction.
The examples illustrate the invention.
Example 1 Crystallography Initial phases for human 20S proteasomes were determined by molecular replacement using the murine 20S structure (PDB ID: 3UNE). The model was then optimized by several rounds of interactive manual model building in Coot and refinement in Refmac5. The obtained structures display excellent stereochemistry with typical values for Rwork=
18% and Rfree=
21%, reveal superb electron densities for all 6724 residues and reveal several ligands as present in buffers used for purification and crystallization.
Using a dataset to 1.8 A resolution, we created a reference model. With the availability of this excellent model for the human 20S proteasome, now structure determination takes minutes by automated refinement of the reference model against integrated and scaled X-ray data from related crystals. Bound ligands can then be rapidly identified in difference density maps and modeled interactively in Coot.
Native crystals were soaked with the epoxyketone inhibitors shown in Figure 1.
Co-crystal structures of human 20S proteasomes in complex with these inhibitors at resolutions between 1.9 ¨ 2.1 A (0.3-0.5 A better resolution than presently available structures) were solved. Surprisingly, after refinement of these co-crystal structures, which allow the modelling of all parts of human 20S proteasomes at atomic resolution, it was not possible to visualize the presumed 1,4-morpholine ring structure in the inhibited state. The electron density maps in the new epoxyketone/human 20S proteasome co-crystal structures in all cases did not agree with the formation of a 1,4-morpholine 6-ring. Instead, density for an additional atom became clearly visible, which is consistent with a 7-ring structure. In fact, modelling the cyclic molecule visible in the inhibited state formed by the reaction of the epoxyketone inhibitors with the active site catalytic threonine amino acid revealed that it represents a 1,4-oxazepane 7-ring structure (Figure 2).
The observation of a 1,4-oxazepane structure contrasts with previously presumed chemical inhibition mechanisms of 20S proteasomes by epoxyketones. Therefore, a control experiment was performed to ensure that the observation of this 7-membered ring structure is true and the modelling of the 1,4-oxazepane structure in the inhibited proteasome active site is justified. Additionally, this control experiment should provide insight into the chemical inhibition mechanism by which the 7-ring structure is formed upon proteasome inhibition. For this control experiment, the co-crystal structures determined using the epoxyketone inhibitors epoxomicin and dihydroeponemycin were compared. Epoxomicin contains an epoxide group with a methyl ligand at the carbon atom, where the nucleophilic attack is presumed to occur in order to form the presumed 1,4-morpholine inhibited ring structure (Figure 3, top left).
Additionally, after formation of the presumed 1,4- morpholine structure ring opening of the epoxide at the carbon atom in a-position to the ketone should yield a stereo center, which contains both a methyl and a methanolic group (Figure 3, right panel) (Groll et al., /oc. cit.).
Dihydroeponemycin in contrast already contains a methanolic ligand at the carbon atom, where the nucleophilic attack is presumed to occur in order to form the proposed 1,4-morpholine inhibited ring structure (Figure 3, top right). As a consequence, after formation of the proposed 1,4-morpholine structure ring opening of the epoxide at the carbon atom in a-position to the ketone should yield a non-chiral center, which contains two methanolic groups. At the resolutions at which both co-crystal structures were determined (1.9 and 2.0 A), it is possible to verify if this is the case. Surprisingly however, the electron density maps of both structures revealed that the inhibited state is formed by the covalent attack of the electrophilic carbon atom in 13-position to the ketone (Figure 3, bottom panels), excluding the possibility that a 1,4-morpholine ring structure is formed in the inhibited state by the absence of electron density compatible with a methanolic group in the case of epoxomicin and two methanolic groups in dihydroeponemycin.
Attempts to model the electron density in the active site of the dihydroeponemycin complex by a 1,4-morpholine ring structure linkage were unsuccessful (Figure 4). 1,4-morpholine linkage refinement resulted in a severely distorted molecular geometry characterized by the elongation of the N4-carbon bonds by 0.1-0.2 A, shortening of the C5-alcohol carbon bond by 0.1 A and deviation of the methyl-05-alcohol bond angle by -20 degrees off the expected value. Additionally, the methyl carbon exhibited a van-der-Waals distance of 3.0 A to the Arginine 19 and Tyrosine 169 main chain oxygen atoms, which is too close.
Moreover, strong negative difference density peaks in difference maps contoured at 5 sigma levels at the C5 , methanol oxygen of the 1,4-morpholine ring model, as well as positive density peaks contoured at 4.5 sigma levels close to positions 4 and 5 of our 1,4-oxazepane ring model remained after this 1,4-morpholine ring refinement. In contrast, no residual difference (neither negative nor positive) density was present in the refined 1,4-oxazepane linkage in density maps contoured above 2.3 sigma.
Example 2 Synthesis , , , .
, >QLOel HN OH ____ 1. EDC, DMAP, 9--0)FIN 0 * Mel, --)----di'L FIN
0 *
(1) 0 MeIdrum acid o 0 K2CO3 o 0 2.BnOH (2) (3) .
, TEA, ' CH2Cl2 .
, o o o 0 H H
\ AN
, _____________________________________________________________ H2N
NJL 0 , ___________ N 0 a HOBt N 0 -,.., 0 Methal101 N 0 -, 0 EDC, o o (6) ? (5) ?
peptide (18) (4) N-Hydroy- i.
succinimide, EDC
µ' I
0 o syt,) jy Li li o,IA
---i 1 11 ---:--"-N
r H
(7) ?
Scheme 3: Synthesis of NHS-ester. Details are given below; see steps A to F.
0 0,c,"' ' 1 _ 1 il 9'-'051'HN __ OH
MeNHOMe, Ha ...)---01HN N' __________ o 0 NEt3, BOB, CH2Cl2 o i o 0-(1) (8) (8) (9-1) ITFA, CH2Cl2 0 i o o o o fyi jc) N t, 1, ./
____eyLEXNHAN ,0 , 0\
MeCOH, /YL HI N N 0 \ EH (1::: II H
, H r H
Isl- 0 ,-.7 0 p-TSOH
,___,s o -,..., 7 (12) (11) ? peptide (18) (10) Scheme 4: Synthsesis of p-keto aldehyde. Details are given below; see steps G
to K.
, , , , , >L0j1,) N,c0H >LoiNfy0 ___________ fy0 T, DMAP, TFA, CH2Cl2 H2NEA HOBt/HBTU, o Benzyl chloro- 0 0 DIEA 0 (13) formate (14) (15) peptide (13) (16) TFA, CH2Cl2 OH
NifrN--- -0 H2NNOio 0 7,0 H2, Pd/C, o HOBt/HBTU, 0 (19) (18) Methanol DIEA (17) I ?
Nrq co2H
Scheme 5: Synthesis of tripeptide. Details are given below; see steps L to Q.
A) To a solution of N-Boc-L-Phenylalanine (1) in CH2Cl2 is added a EDC (1 eq.), DMAP (1 eq.) and Meldrum's acid (1 eq.). The reaction is stirred at room temperature for 17 hours, then poured into 1 M HCl. The layers are separated and the aqueous layer is extracted three times with CH2Cl2. The organic layers are combined, washed with brine, dried over MgSO4 and concentrated in vacuum. The residue is heated to 80 C in toluene and after the addition of benzyl alcohol (1 eq.) for 4 hours. The solvent is the removed in vacuum and the residue purified by flash chromatography and elution with ethyl acetate to yield (2).
B) A solution of (2), methyl iodide (3 eq.) and potassium carbonate (2 eq.) in acetone is heated under reflux for 17 hours. 2 volume equivalents of water are added and the resulting mixture extracted three times with 2 volume equivalents ethyl acetate. The organics are combined, dried over MgSO4 and concentrated in vacuum. The residue is purified by preparative HPLC in 0.1 % formic acid in water, with a gradient to 0.1 %
formic acid in acetonitrile to give (3).
C) A solution of (3) is stirred in a 10 % TFA solution in CH2Cl2 for 17 hours at room temperature. The solvent is subsequently removed in vacuum to yield (4).
D) To (4) (1 eq.) in CH2Cl2 and triethylamine (0.001 eq.) is added (19) (1 eq.), HOBT (0.2 eq.) and EDC (2 eq.). The solution is stirred at 25 C for 24 hours and then washed three times with saturated sodium hydrogencarbonate solution, once with deionized water and brine each, and the organic layer is dried over MgSO4. The solvent is removed in vacuum and the residue purified by flash chromatography eluting with 1:1 ethyl acetate:n-hexane to yield (5).
E) (5) is stirred in methanol containing 10% Pd/C under a hydrogen atmosphere (1 atm).
After 2 hours the mixture is filtered through celite and the solvent removed in vacuo to the product (6).
F) To (6) in CH2Cl2 is added, EDC (2 eq.) and N-Hydroxysuccinimide (2 eq.) and the mixture stirred for 2 hours. The solvent is then removed in vacuo and the residue purified by flash chromatography, eluting with 1:5 ethyl acetate:n-hexane to yield (7).
G) To a stirred solution of Boc-L-Phenylalanine in CH2C12 is added 0,N-dimethylhydroxylamine hydrochloride (1 eq.), triethylamien (2 eq.) and BOP (1 eq.). After 3.5 hours the solution is diluted 4-fold with CH2C12 and washed three times with 3 M HCL, three times with saturated sodium hydrogencarbonate and three times with brine. The organic layer is then dried over MgSO4, the solvent removed in vacuo and the residue purified by flash chromatography with 1:3 ethyl acetate:n-hexane to yield (8).
H) The Weinreb amide (8) in THF under an Argon atmosphere is cooled to 0 C
and 1,3-Dioxacyclopenty1-2-MgBromide (5 eq.) in THF added dropwise. The reaction is allowed to reach 25 C and after 4 hours of stirring, is quenched with 1 M HCl forming a precipitate. The precipitate is removed by filtration and washed three times with ethyl acetate. The combined organics are then washed with brine, dried over MgSO4 and the solvent removed in vacuum.
The residue is then purified by flash chromatography using 1:4 ethyl acetate:
n-hexane as an eluent to yield (9).
1) A solution of (9) is stirred in a 10 % TFA solution in CH2C12 for 17 hours at room temperature. The solvent is subsequently removed in vacuum to yield (10).
J) To (10) (1 eq.) in CH2C12 and triethylamine (0.001 eq.) is added (19) (1 eq.), HOBT (0.2 eq.) and EDC (2 eq.). The solution is stirred at 25 C for 24 hours and then washed three times with saturated sodium hydrogencarbonate solution, once with deionized water and brine each, and the organic layer is dried over MgSO4. The solvent is removed in vacuo and the residue purified by flash chromatography eluting with 1:1 ethyl acetate:n-hexane to yield (11).
K) A solution of (11) and p-Ts0H (0.1 eq.) in acetaldehyde (0.5 eq.) is stirred under an argon atmosphere at 15 C for 23 hours. The solvent is then removed in vacuum and the residue purified by flash chromatography, eluting with 1:5 ethyl acetate:n-hexane to yield (12).
L) To a solution of Boc-methylserine (13) in DCM (Dichlormethane) TEA
(Triethylamine) and DMAP (4-Dimethylaminopyridine) are added. The resulting solution is cooled to -5 C, and benzyl chloroformate is then slowly added via an addition funnel under an atmosphere of argon. The reaction is kept at the same temperature for 3 h and then diluted with brine. The layers are separated, and the aqueous layer is extracted with DCM. The organic layers are combined and dried over Na2SO4. The Na2SO4 is removed by filtration, and the volatiles are removed under reduced pressure. The resulting residue is purified by flash chromatography using a mixture of hexane and ethyl acetate to provide intermediate (14) as white solid.
M) To a 0 C solution of intermediate (14) in DCM TFA (Trifluoroacetic acid) is added slowly via a funnel. The reaction is kept at the same temperature for 1 h, concentrated, and dried under high vacuum overnight. The resulting residual TFA salt (15) is used in the next step without further purification.
N) To a -5 C mixture of aforementioned TFA salt (15), Boc-methylserine (13), HOBt (Hydroxybenzotriazole), and HBTU (2-(1H-benzotriazol-1-y1)-1,1,3,3-tetramethyluronium hexafluorophosphate) in THF (Tetrahydrofuran) (600 mL) is added DIEA slowly via an addition funnel. The reaction is kept at the same temperature for 4 h, followed by dilution with Et0Ac (Ethylacetate) and brine. The layers are separated, and the aqueous layer is extracted with Et0Ac (2 x 300 mL). The organic layers are combined and dried over Na2SO4. The Na2SO4 is removed by filtration, and the volatiles are removed under reduced pressure. The resulting residue is purified by flash chromatography using a mixture of hexane and ethyl acetate to provide dipeptide (16) as white solid.
0) To a 0 C solution of aforementioned intermediate (16) in DCM was added TFA
slowly via an addition funnel. The reaction is kept at the same temperature for 2 h, concentrated, and dried under high vacuum overnight. The resulting residual TFA salt (17) is used in the next step without further purification.
P) To a -5 C mixture of TFA salt (17), 2-methylthiazole-5- carboxylic acid, HOBt, and HBTU
in THF is added DIEA slowly. The reaction is kept at the same temperature for 4 h and then diluted with Et0Ac and brine. The layers are separated, and the aqueous layer is extracted with Et0Ac. The organic layers are combined and dried over Na2SO4. The Na2SO4 is removed by filtration, and the volatiles are removed under reduced pressure.
The resulting residue is purified by flash chromatography using a mixture of hexane and ethyl acetate to provide benzyl ester (18) as white solid.
Q) (18) is stirred in methanol containing 10% Pd/C under a hydrogen atmosphere (1 atm).
After 2 hours the mixture is filtered through celite and the solvent removed in vacuum to the product (19).
Example 3 Proteasome assays Activity measurement Preferred in vitro Assay.
All kinetic measurements were performed using a FluoroMax0-4 fluorescence spectrophotometer (Horiba Scientific). Succinyl-Leucine-Leucine-Valine-Tyrosine-7-amido-4-methylcoumarin (Suc-LLVY-AMC, Bachem) was used as substrate to determine the chymotryptic-like activity of the 135 catalytic active site of the human 20S
proteasome (R. L.
Stein, F. Melandri, L. Dick, Kinetic characterization of the chymotryptic activity of the 20S
proteasome. Biochemistry 35, 3899-3908 (1996)). The fluorescence emission of hydrolyzed AMC was continuously monitored at 460 nm (Aex = 380 nM). The reaction temperature was kept at 37 C for all measurements and the reaction buffer for enzymatic assays specified in Table S1 was used. Suc-LLVY-AMC and inhibitors (such as Oprozomib, Dihydroeponemycin, Z-LLY-Ketoaldehyde; "Sue" designating Succinyl and "Z"
designating Benzyloxycarbonyl) were dissolved in DMSO and stored at -80 C until usage.
The DMSO
concentration did not exceed 2% (v/v) in any measurement.For kinetic characterization of Suc-LLVY-AMC conversion, 0.035 mg/mL (50 nM) human 20S proteasome in reaction buffer was pre-incubated for 3 minutes at 37 C. The reaction was started by the addition of substrate and the fluorescence signal was measured continuously. For determination of the first-order rate constant of inhibition of the respective inhibitors, the reaction mixture containing reaction buffer, 150 pM substrate and either Oprozomib (50 pM), Dihydroeponemycin (50 pM) or Z-LLY-Ketoaldehyde (15 pM) were pre-incubated at 37 C for 3 minutes. The reaction was then started by the addition of human 20S
proteasome to a final concentration 50 nM. The fluorescence signal was measured continuously.
Data were analyzed and fitted with OriginPro 9.1 and KaleidaGraph 4.03. The equation shown in Figure 5 was used to analyze the chymotryptic-like catalytic activity and catalytic activation of the 20S proteasome. For the determination of the first-order inactivation rate constants, equations were used that contained either two exponential terms in case of Z-LLY-Ketoaldehyde, or two exponential terms plus a linear term for epoxyketones (Oprozomib and Dihydroeponemycin). The first of the two exponential terms accounts for the catalytic activation, whereas the second exponential term represents the catalytic inactivation by inhibitory action. The linear term in case of the epoxyketones was used to account for the residual activity of the proteasome after inactivation.
Alternative kinetic assay.
Time point measurements of the activity assays are performed to acquire an initial tendency of inhibitor binding. Different concentrations of 20S proteasome are used for each active site:
0.05 mg/ml for CL (Chymotryptic-like activity) and PGPH (Peptidyl-glutamyl peptide hydrolyzing activity) and 0.075 mg/ml for TL (Tryptic-like activity). The final reaction volume is 30 p1/well. A total number of five repetitions are performed to obtain root mean square deviation (RMSD), including a blank and a 100% initial activity reaction. The steps are as follows.
(1) A master mix is prepared: Respective amount proteasome (according to PGPH, TL, or CL
activity determination).
(2) Eppendorf tubes are prepared with the amount of the respective inhibitor to be analysed;
e.g. 500 pM concentration of the ligand in 30 pl is 1.5 pl per assay of a 10 mM inhibitor stock solution.
(3) 28.5 pl of the master mix is added to each Eppendorf tube. This solution is incubated for min at room temperature and transferred to the respective wells of the 96 well plates.
(4) Following incubation, 1 pl of a 7.5 mM stock solution of substrate for the caspase, 10 chymotryptic or tryptic site is added, giving a final substrate concentration of 250 pM. The plate is centrifuged and incubated at RT for 1 h.
(5) 300 pl of buffer is added to the reaction and the remaining proteasome activity is subsequently recorded by fluorescence at Ex (Excitation wavelength) 360 nm -Em (Emission wavelength) 460 nm.
15 (6) The remaining activity is calculated using the blank and 100%
initial activity.
Once proteasome inhibition is observed through the time point measurements, the half maximal inhibitory concentration (IC50) measurements can be performed. The percentage of the remaining activities is then plotted against the log concentration of the respective inhibitor. The obtained data are fitted with a conventional statistical program, for example as described in: Groll M, Gallastegui N, Marechal X, et al (2010) 20S Proteasome Inhibition:
Designing Non-Covalent Linear Peptide Mimics of the Natural Product TMC-95A.
ChemMedChem 5:1701-1705.
.. Reference for assay:
A description of an activity assay can be found in Gallastegui, N., & Groll, M. (2012).
Analysing Properties of Proteasome Inhibitors Using Kinetic and X-Ray Crystallographic Studies. In Methods in Molecular Biology (Vol. 832, pp. 373-390).
doi:10.1007/978-1-61779-474-2_26.
Cellular assays.
A further example is the Z-Sensor Proteasome assay from Takara/ Clontech.
ZsProSensor-1 is a proteasome-sensitive fluorescent reporter. It is a fusion of a bright green fluorescent protein (Exmax = 496 nm, Emmax = 506 nm) with a degradation domain which targets the protein for rapid degradation by the proteasome. The cells emit green fluorescence when there is a drop in proteasome activity.
Alternative methods:
Proteasome-GloTM Chymotrypsin-Like, Trypsin-Like and Caspase-Like Cell-Based Assays (Promega).
GFP-Assay: Bence N, Bennett E, Kopito R, Deshaies R. Application and analysis of the GFP(u) family of ubiquitin-proteasome system reporters. Ubiquitin and Protein Degradation, Pt B. 2005;399:481-490.
A cellular assay for the immunoproteasome is the following:
Fluorogenic in vitro assay (Immunoproteasome): (Basler, M., & Groettrup, M.
(2012).
Immunoproteasome-Specific Inhibitors and Their Application. In Methods in Molecular Biology (Vol. 832, pp. 391-401). doi:10.1007/978-1-61779-474-2_27) In order to test whether your IP inhibitor is cell permeable, the following method based on proteasome immuno- precipitation and in vitro activity assay can be used. The steps are as follows.
(1) Incubate cells for 2 h with desired concentration of IP inhibitors in cell culture media at 37 C. We normally use mouse splenocytes (one spleen per sample). As control, use an equal number of cells without inhibitor.
(2) Wash cells three times with PBS to remove unbound inhibitor.
(3) Lyse cells in 500 pl lysis buffer and incubate for 20 min on ice.
(4) Centrifuge the lysates for 10 min at 20,800 x g to remove debris.
(5) Discard pellet and add 3 pl of polyclonal rabbit-anti-mouse proteasome antibody and 50 pl protein A microbeads to the supernatant and incubate for 30 min on ice.
(6) Insert p column into magnet.
(7) Equilibrate p column with 1 ml NET-TON buffer.
(8) Load lysate on p column and discard flow through.
(9) Wash column twice with 1 ml NET-TON buffer and three times with NET-T
buffer.
.. (10) Add 50 pl of a fluorogenic substrate and incubate column for 30 min at 37 C.
(11) Add 200 pl lysis buffer and collect eluate.
(12) Measure the fluorescence in 100 pl of the eluate (96-well plate, flat bottom, black). The fluorescence in the eluate corresponds to the activity of the retained proteasome in the column.
LacZ assay (Immunoproteasome); see Basler, M., & Groettrup, M. (2012).
Immunoproteasome-Specific Inhibitors and Their Application. In Methods in Molecular Biology (Vol. 832, pp. 391-401). doi:10.1007/978-1-61779-474-2_27.
Numerous MHC-I restricted CD8+ T-cell epitopes have been described to be dependent on IP subunits. Investigating the pro- cessing of such T-cell epitopes can test specificity of IP
inhibitors. In order to analyse the LMP7-selective inhibitor PR-957, we investigated the male HY-derived CTL-epitope UTY 246-254, which was reported to be LMP7 dependent.
Therefore, we treated male splenocytes with PR-957 and detected MHC-I
presented UTY
246-254 peptides with the help of UTY 246-254 -specific T-cell hybridomas in lacZ assays.
(1) Remove spleen of one male and one female mouse and take up spleen in 5 ml RPM!
10% FCS.
(2) Make a single-cell suspension by pressing spleen through a grid.
(3) Centrifuge cells for 5 min at 347 x g and discard supernatant.
(4) Lyse the erythrocytes by resuspending cells in 5 ml pre-warmed 1.66% (w/v) solution (in 15-ml tubes).
(5) Incubate for 2 min at room temperature.
(6) Fill up to 15 ml with RPMI 10% FCS and centrifuge cells for 5 min at 347 x g and discard supernatant.
(7) Wash cells with 15 ml PBS, centrifuge cells for 5 min at 347 x g, and discard supernatant.
(8) Take up cells in 5 ml RPMI 10% FCS and count cells using a Neubauer chamber.
(9) Incubate 10 7 splenocytes in 3 ml RPM! 10% FCS per well (6-well tissue culture plate).
(10) Add desired amounts of inhibitor. You need one well of male splenocytes without inhibitor for comparison of untreated and treated samples. For female splenocytes, you only need one well without inhibitor.
(11) Incubate overnight at 37 C.
(12) Harvest splenocytes, wash cells twice with 15 ml PBS, and count splenocytes.
LacZ assay (Immunoproteasome); see Basler, M., & Groettrup, M. (2012).
Immunoproteasome-Specific Inhibitors and Their Application. In Methods in Molecular Biology (Vol. 832, pp. 391-401). doi:10.1007/978-1-61779-474-2_27.
Numerous MHC-I restricted CD8+ T-cell epitopes have been described to be dependent on IP subunits. Investigating the pro- cessing of such T-cell epitopes can test specificity of IP
inhibitors. In order to analyse the LMP7-selective inhibitor PR-957, we investigated the male HY-derived CTL-epitope UTY 246-254, which was reported to be LMP7 dependent.
Therefore, we treated male splenocytes with PR-957 and detected MHC-I
presented UTY
246-254 peptides with the help of UTY 246-254 -specific T-cell hybridomas in lacZ assays.
(1) Remove spleen of one male and one female mouse and take up spleen in 5 ml RPM!
10% FCS.
(2) Make a single-cell suspension by pressing spleen through a grid.
(3) Centrifuge cells for 5 min at 347 x g and discard supernatant.
(4) Lyse the erythrocytes by resuspending cells in 5 ml pre-warmed 1.66% (w/v) solution (in 15-ml tubes).
(5) Incubate for 2 min at room temperature.
(6) Fill up to 15 ml with RPMI 10% FCS and centrifuge cells for 5 min at 347 x g and discard supernatant.
(7) Wash cells with 15 ml PBS, centrifuge cells for 5 min at 347 x g, and discard supernatant.
(8) Take up cells in 5 ml RPMI 10% FCS and count cells using a Neubauer chamber.
(9) Incubate 10 7 splenocytes in 3 ml RPM! 10% FCS per well (6-well tissue culture plate).
(10) Add desired amounts of inhibitor. You need one well of male splenocytes without inhibitor for comparison of untreated and treated samples. For female splenocytes, you only need one well without inhibitor.
(11) Incubate overnight at 37 C.
(12) Harvest splenocytes, wash cells twice with 15 ml PBS, and count splenocytes.
(13) Resuspend cells in RPM! 10% FCS at 107/ml.
(14) Use 96-well round-bottom tissue culture plate and add 150 pl per well to wells A1-D1.
Make four serial threefold dilutions of splenocytes (100 p1/per well).
Make four serial threefold dilutions of splenocytes (100 p1/per well).
(15) Harvest 1-cell hybridomas, count, and resuspend in RPM! 10% FCS at 10^6/ml. (We use the UTY 246-254 -specific 1-cell hybridoma (5).)
(16) Add 100 pl of T-cell hybridomas per well (A1-A4; B1-134). Add to half of your samples (C1-C4; D1-D4) 100 pl RPM! 10% FCS as background control.
(17) Female splenocytes are used as negative control and untreated male splenocytes as positive control and for comparison. You can make an additional positive control adding synthetic peptide (we use UTY 246-254 peptide at a concentration of 10^-7 M) to female splenocytes.
(18) Incubate o/n at 37 C.
(19) Centrifuge plate at 541 x g for 90 s and discard supernatant.
(20) Add 100 pl lacZ buffer and incubate at 37 C.
(21) Measure absorbance at 570/620 nm when colour change is visible (approx.
after 1-3 h).
Example 4 Alternative synthesis Synthesis of tripeptide 28584 0 ,0 0 0 ro o H o boc,Nf NX1r r OH boc 0 H2Nfi "bn-u- boc, N bn K
H2NAIrN")1µ'0"bn ii A.Iprc%11`)% /Li Scheme 1: Synthesis route of tripeptide 28584.
The synthesis of the tripeptide 28584 was successfully carried out according to the literature procedure. The formation of the Benzylester 28579 was performed in 4 g scale and 4.6 g product was obtained (>95% purity by 1H-NMR, 98% purity by LC/MS, 82% yield).
The following Boc-deprotection of 28579 led to 4.8 g of 28580 in quant. yield and 95% purity by 1H-NMR and 86% purity by LC/MS.
The peptide coupling was performed on a 2 g scale and 1.8 g of 28581 was obtained (95%
purity by LC/MS, 90% purity by 1H-NMR, 73% yield).
Synthesis of 28582 was carried out in 1.7 g scale and 1.7 g product (28582) was obtained as TFA salt (quant. yield, 90% purity by 1H-NMR).
After amide formation of 2-Methyl-5-thiazolecarboxylic acid with 28582, 1.5 g of 28583 was obtained (80% yield, 93% purity by 1H-NMR; >95% by LC/MS).
, The benzyl ester deprotection of 28583 with 10% Pd/C was performed on 1.5 g scale and 1.0 g 28584 was obtained (79% yield, 95% purity by 11-I-NMR and LC/MS). It was found out that the benzyl ester deprotection requires more than catalytic amount 10% Pd/C.
For fast deprotection at least equal amount of Pd/C is needed compared to the used amount of , 28583.
.
, Synthesis of NHS-Ketoester 28880 and thioester 29502, 29865 , , , , lic. OA N '74 ED:' MAP' - icoAg - ' X0IN -Niro 141 .
H 0 ID,i 0 99 H 1-1 lifteldn.cna acid 0 0 0.õ..,.
28864 /\ 28865 ..., Mel, .
%-= ivZO, E
-ir P"'eptide N (:)." * HaN ') ' ) - - D-- ¨ X01 . 1109t, TFA, il 0 0 0 ar2CT2 0 0 28878 Pagide. 28077 2' 9f , I
o o 0 F 1 F12. PEW
methanol Pt lit peyll'Nfyy- OH
;.... 0 I
,rx0 Kfir pi Ar(ry,roli_ ."(sYrOH
PePhde N sA S 0 k.. C., H 144-lyeroxy- i.- 0 0 succi nmide I
= SN.Ac, DX, DMAP SNAc. DCC, DMAP
t I
0 1.(N-y,,A.t4 s di I
Scheme 2: Synthesis of NHS-Ketoester 28880 or thioester 29502 and 29865.
, , , , , The formation of the Meldrum's acid intermediate 28864 was performed by using N-Boc-L-Leu-OH and EDC/DMAP in DCM as reported in the literature. It was observed that under those reaction conditions product with complex mixture of side products was formed. One major side product was identified by LC/MS as cyclized Leucine derivative. The reaction crude has a purity of approx. 30-40% determined by 1H-NMR.
XolN EDC/DMAP XolN 0 X0j54 OH DCM
o o ===K cyclized side product Scheme 3: Reaction of N-Boc-L-Leu-OH to 28864 and the formation of observed cyclized side product.
When 28864 was treated with benzyl alcohol for Meldrum's acid building block opening the desired product 28865 was obtained. From 6.7 g reaction 1.7 g of 28865 was obtained (26%
yield, 85% purity by 11-I-NMR).
The double alkylation of 28865 was carried out by using excess of methyl iodide in the presence of K2CO3 in acetone which led to the formation of 28895 in 30-38%
yield. In the end, out of a 3.7 g scale reaction 1.3 g of 28895 was obtained (38% yield, 95%
purity by 1H-NMR).
The N-Boc deprotection of 28877 was performed using 10% TFA in DCM and was done as reported in the literature. After work up 1H-NMR clearly showed the mixture of compounds.
Another reaction was carried out and it was found out that the reaction was completed in two hours instead of 17 h which was reported in the literature.
The reaction mixture was concentrated at room temperature.
The deprotection was performed shortly before the amide coupling of 28878. 400 mg reaction of 28877 was carried out and the reaction crude (purity 85% by LC/MS) was used immediately for the next reaction step.
HATU was used as a coupling reagent for the synthesis of 28878 successfully.
After work up =
the 11-I-NMR indicated that epimerization was occurred (15% by 1H-NMR). This is corresponding to the reported literature. The synthesis of 28878 was successfully performed in a 100 mg and 300 mg scale by using HATU as coupling reagent. After purification 65 mg (36% yield, purity 95% by LC/MS) and 298 mg (55% yield, purity 95% by LC/MS) product 28878 was obtained. In both cases the presence of epimer was decreased from 15 mol% to 8 mol%.
The synthesis of 28879 was performed using N,N-dicyclohexylcarbodiimide and N-hydroxysuccinimide in THF/DMF as solvent system. By LC/MS the formation of a peak with the right mass was observed.
After precipitation of dicyclohexylurea in DCM and removal of excess of NHS by washing with water, 25 mg were obtained (48% purity by LC/MS). The crude compound was tried to purify by preparative HPLC on reverse phase column. The fractions were extracted by DCM
in order to avoid hydrolysis/decarboxylation. 0.7 mg with 93% purity and a peak with the right product mass in LC/MS was obtained. 1H-NMR in CDCI3 provided no clear indication due to the small amount of sample.
For structure elucidation, reaction of 28880 was performed on a 140 mg scale by using N,N-dicyclohexylcarbodiimide and N-hydroxysuccinimide (NHS) in Et0Ac/DMF as solvent system. LC/MS analysis showed the formation of a peak with the right product mass. After precipitation of dicyclohexylurea in DCM and removal of excess of NHS by washing with water, 120 mg were obtained (48% purity by LC/MS). The crude was tried to purify by preparative HPLC.
To enhance the coupling efficiency PyBOP was used as a coupling reagent. By using 1.3 eq.
of PyBOP, 2.0 eq. DIPEA and 3.0 eq. NHS a very prominent peak with right product mass was observed also in much higher intensity than before.
In order to prove whether the peak with the right product mass observed in LC/MS is an artefact or belongs to the desired compound 28880, it was treated with Me0H to form the methylester of 28880. LC/MS analysis showed that the peak with the mass of the expected NHS-ester was disappeared and the formation of a peak with the right mass of the methylester was observed.
Purification was done by doing two times short plug filter column chromatography. In the first case the reaction mixture was directly filtered through a pad of silica without any solvent removal after the reaction. THF was used as eluent. After concentration of this above mentioned fraction, compound was purified again by short column chromatography using .. DCM/THF mixture as eluent. 9.8 mg of product was obtained (62% purity by LC/MS). Due to very small amount the purity of product cannot be improved further. However, 11-I-NMR is corresponding to the product. For larger scale the purification was improved by optimizing the column chromatography using c-hexane/THF as solvent mixture.
Another 100 mg reaction was performed by using 1.3 eq. of PyBOP, 2.0 eq. DIPEA
and 3.0 eq. NHS as coupling conditions. Purification was done by doing short plug filter column chromatography. In the first case the reaction mixture was filtered through a pad of silica without any concentration. THF was used as eluent. After concentration of the above mentioned fraction, compound was purified by column chromatography using c-hexane/THF
mixture as eluent. 47 mg of desired title compound 28880 was obtained with purity of 88% by 1H-NMR, containing 13.5 mol% of decarboxylated 28879.
In conclusion, 47 mg of 28880 was delivered successfully in 88% purity by 1H-NMR.
after 1-3 h).
Example 4 Alternative synthesis Synthesis of tripeptide 28584 0 ,0 0 0 ro o H o boc,Nf NX1r r OH boc 0 H2Nfi "bn-u- boc, N bn K
H2NAIrN")1µ'0"bn ii A.Iprc%11`)% /Li Scheme 1: Synthesis route of tripeptide 28584.
The synthesis of the tripeptide 28584 was successfully carried out according to the literature procedure. The formation of the Benzylester 28579 was performed in 4 g scale and 4.6 g product was obtained (>95% purity by 1H-NMR, 98% purity by LC/MS, 82% yield).
The following Boc-deprotection of 28579 led to 4.8 g of 28580 in quant. yield and 95% purity by 1H-NMR and 86% purity by LC/MS.
The peptide coupling was performed on a 2 g scale and 1.8 g of 28581 was obtained (95%
purity by LC/MS, 90% purity by 1H-NMR, 73% yield).
Synthesis of 28582 was carried out in 1.7 g scale and 1.7 g product (28582) was obtained as TFA salt (quant. yield, 90% purity by 1H-NMR).
After amide formation of 2-Methyl-5-thiazolecarboxylic acid with 28582, 1.5 g of 28583 was obtained (80% yield, 93% purity by 1H-NMR; >95% by LC/MS).
, The benzyl ester deprotection of 28583 with 10% Pd/C was performed on 1.5 g scale and 1.0 g 28584 was obtained (79% yield, 95% purity by 11-I-NMR and LC/MS). It was found out that the benzyl ester deprotection requires more than catalytic amount 10% Pd/C.
For fast deprotection at least equal amount of Pd/C is needed compared to the used amount of , 28583.
.
, Synthesis of NHS-Ketoester 28880 and thioester 29502, 29865 , , , , lic. OA N '74 ED:' MAP' - icoAg - ' X0IN -Niro 141 .
H 0 ID,i 0 99 H 1-1 lifteldn.cna acid 0 0 0.õ..,.
28864 /\ 28865 ..., Mel, .
%-= ivZO, E
-ir P"'eptide N (:)." * HaN ') ' ) - - D-- ¨ X01 . 1109t, TFA, il 0 0 0 ar2CT2 0 0 28878 Pagide. 28077 2' 9f , I
o o 0 F 1 F12. PEW
methanol Pt lit peyll'Nfyy- OH
;.... 0 I
,rx0 Kfir pi Ar(ry,roli_ ."(sYrOH
PePhde N sA S 0 k.. C., H 144-lyeroxy- i.- 0 0 succi nmide I
= SN.Ac, DX, DMAP SNAc. DCC, DMAP
t I
0 1.(N-y,,A.t4 s di I
Scheme 2: Synthesis of NHS-Ketoester 28880 or thioester 29502 and 29865.
, , , , , The formation of the Meldrum's acid intermediate 28864 was performed by using N-Boc-L-Leu-OH and EDC/DMAP in DCM as reported in the literature. It was observed that under those reaction conditions product with complex mixture of side products was formed. One major side product was identified by LC/MS as cyclized Leucine derivative. The reaction crude has a purity of approx. 30-40% determined by 1H-NMR.
XolN EDC/DMAP XolN 0 X0j54 OH DCM
o o ===K cyclized side product Scheme 3: Reaction of N-Boc-L-Leu-OH to 28864 and the formation of observed cyclized side product.
When 28864 was treated with benzyl alcohol for Meldrum's acid building block opening the desired product 28865 was obtained. From 6.7 g reaction 1.7 g of 28865 was obtained (26%
yield, 85% purity by 11-I-NMR).
The double alkylation of 28865 was carried out by using excess of methyl iodide in the presence of K2CO3 in acetone which led to the formation of 28895 in 30-38%
yield. In the end, out of a 3.7 g scale reaction 1.3 g of 28895 was obtained (38% yield, 95%
purity by 1H-NMR).
The N-Boc deprotection of 28877 was performed using 10% TFA in DCM and was done as reported in the literature. After work up 1H-NMR clearly showed the mixture of compounds.
Another reaction was carried out and it was found out that the reaction was completed in two hours instead of 17 h which was reported in the literature.
The reaction mixture was concentrated at room temperature.
The deprotection was performed shortly before the amide coupling of 28878. 400 mg reaction of 28877 was carried out and the reaction crude (purity 85% by LC/MS) was used immediately for the next reaction step.
HATU was used as a coupling reagent for the synthesis of 28878 successfully.
After work up =
the 11-I-NMR indicated that epimerization was occurred (15% by 1H-NMR). This is corresponding to the reported literature. The synthesis of 28878 was successfully performed in a 100 mg and 300 mg scale by using HATU as coupling reagent. After purification 65 mg (36% yield, purity 95% by LC/MS) and 298 mg (55% yield, purity 95% by LC/MS) product 28878 was obtained. In both cases the presence of epimer was decreased from 15 mol% to 8 mol%.
The synthesis of 28879 was performed using N,N-dicyclohexylcarbodiimide and N-hydroxysuccinimide in THF/DMF as solvent system. By LC/MS the formation of a peak with the right mass was observed.
After precipitation of dicyclohexylurea in DCM and removal of excess of NHS by washing with water, 25 mg were obtained (48% purity by LC/MS). The crude compound was tried to purify by preparative HPLC on reverse phase column. The fractions were extracted by DCM
in order to avoid hydrolysis/decarboxylation. 0.7 mg with 93% purity and a peak with the right product mass in LC/MS was obtained. 1H-NMR in CDCI3 provided no clear indication due to the small amount of sample.
For structure elucidation, reaction of 28880 was performed on a 140 mg scale by using N,N-dicyclohexylcarbodiimide and N-hydroxysuccinimide (NHS) in Et0Ac/DMF as solvent system. LC/MS analysis showed the formation of a peak with the right product mass. After precipitation of dicyclohexylurea in DCM and removal of excess of NHS by washing with water, 120 mg were obtained (48% purity by LC/MS). The crude was tried to purify by preparative HPLC.
To enhance the coupling efficiency PyBOP was used as a coupling reagent. By using 1.3 eq.
of PyBOP, 2.0 eq. DIPEA and 3.0 eq. NHS a very prominent peak with right product mass was observed also in much higher intensity than before.
In order to prove whether the peak with the right product mass observed in LC/MS is an artefact or belongs to the desired compound 28880, it was treated with Me0H to form the methylester of 28880. LC/MS analysis showed that the peak with the mass of the expected NHS-ester was disappeared and the formation of a peak with the right mass of the methylester was observed.
Purification was done by doing two times short plug filter column chromatography. In the first case the reaction mixture was directly filtered through a pad of silica without any solvent removal after the reaction. THF was used as eluent. After concentration of this above mentioned fraction, compound was purified again by short column chromatography using .. DCM/THF mixture as eluent. 9.8 mg of product was obtained (62% purity by LC/MS). Due to very small amount the purity of product cannot be improved further. However, 11-I-NMR is corresponding to the product. For larger scale the purification was improved by optimizing the column chromatography using c-hexane/THF as solvent mixture.
Another 100 mg reaction was performed by using 1.3 eq. of PyBOP, 2.0 eq. DIPEA
and 3.0 eq. NHS as coupling conditions. Purification was done by doing short plug filter column chromatography. In the first case the reaction mixture was filtered through a pad of silica without any concentration. THF was used as eluent. After concentration of the above mentioned fraction, compound was purified by column chromatography using c-hexane/THF
mixture as eluent. 47 mg of desired title compound 28880 was obtained with purity of 88% by 1H-NMR, containing 13.5 mol% of decarboxylated 28879.
In conclusion, 47 mg of 28880 was delivered successfully in 88% purity by 1H-NMR.
Claims (15)
1. A compound of formula (I) wherein X is C=O, C=S or B-OH;
Y is an electrophile and Z is a leaving group, or Y~Z is an electrophile;
R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery;
or (b) a group binding between subunits .beta.1 and .beta.2 of a proteasome;
R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
Y is an electrophile and Z is a leaving group, or Y~Z is an electrophile;
R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery;
or (b) a group binding between subunits .beta.1 and .beta.2 of a proteasome;
R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
2. The compound of claim 1(a), wherein said first group is a peptidic group comprising or consisting of at least two amino acids, or a corresponding peptidomimetic, wherein X takes the place of the carbonyl group or of the .alpha.-carbon of the C-terminal amino acid of said peptidic group, and said second group, if present, is bound to the N-terminus of said peptidic group.
3. The compound of claim 1 or 2, wherein Y~Z is (a) CH=O, CH2-I, CH2-Br, CH2-Cl, CH2-OPO(OH)2, CH2-OTs, CO-NHS or CH=CH2, wherein OTs is p-toluene sulfonyloxy and NHS is N-oxy-succinimide; or (b) O-I, O-Br, O-CI, S-I, S-Br or S-I.
4. The compound of any one of claims 1 to 3, wherein R2 and R3 are identical and preferably methyl, methoxy or -CH2OH.
5. The compound of any one of claims 1 to 4, wherein X is C=O and Y~Z is CH=O or CO-NHS.
6. The compound of claims 1 to 5, wherein said peptidic group consists of three a-amino acids and wherein preferably (a) the N-terminal amino acid is selected from Ser(OMe), Leu, Phe and Ala; the middle amino acid is selected from Ser(OMe), Leu, Phe and Ala; and/or the C-terminal amino acid is selected from Phe, Tyr, Leu, Ser(OMe) and Ala; or (b) said peptidic group consists of Ser(OMe)-Ser(OMe)-Phe, Leu-Leu-Tyr or Ala-Ala-Ala.
7. The compound of claim 1, wherein said compound has formula (IIa) or (IIb) wherein R1 is 2-methyl thiazol-5-yl carbonyl Ser(OMe)-Ser(OMe)-NH-CH(CH2-C6H5).
8. Use of a compound as defined in any one of claims 1 to 7 as a proteasome inhibitor.
9. A method of inhibiting a proteasome, said method comprising bringing into contact a proteasome and a compound as defined in any one of claims 1 to 7, provided that methods for treatment of the human or animal body by therapy and diagnostic methods practised on the human or animal body are excluded and/or said method is performed in vitro or ex vivo.
10. A medicament or lead compound for developing a medicament comprising or consisting of a compound as defined in any one of claims 1 to 7.
11. A compound as defined in any one of claims 1 to 7 for use in a method of treating, ameliorating or preventing cancer, an autoimmune disease, muscular dystrophy, emphysema, or cachexia accompanying cancer or AIDS.
12. The compound for use of claim 11, wherein (a) said cancer is a lymphoid malignancy, preferably selected from multiple myeloma (MM) including relapsed and refractory MM; non-Hodgkin lymphoma such as B-cell lymphomas including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), and Waldenström macroglobulinaemia; or (b) said autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, Sjörgen's syndrome or scleroderma.
13. A method of identifying a compound capable of inhibiting a proteasome, said method comprising bringing into contact a test compound of formula (III) wherein R4 is an organic group, and X, Y, Z, R2 and R3 are as defined in any one of claims 1 or 3 to 5, with a proteasome, wherein a decreased activity of the proteasome in presence of said test compound as compared to the absence thereof is indicative of said test compound being a compound capable of inhibiting a proteasome.
14. The method of claim 13, wherein said activity is a proteolytic activity, preferably selected from caspase-like, trypsin-like and chymotrypsin-like activity.
15. A compound of formula (IV) wherein A is selected from NH-NH2, N3 and a click chemistry functional group;
X, Y, Z, R2 and R3 are as defined in any one of claims 1 or 3 to 5.
X, Y, Z, R2 and R3 are as defined in any one of claims 1 or 3 to 5.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662346203P | 2016-06-06 | 2016-06-06 | |
EP16173057.7 | 2016-06-06 | ||
US62/346,203 | 2016-06-06 | ||
EP16173057 | 2016-06-06 | ||
PCT/EP2017/063699 WO2017211818A1 (en) | 2016-06-06 | 2017-06-06 | Proteasome inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3026564A1 true CA3026564A1 (en) | 2017-12-14 |
Family
ID=56289289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3026564A Pending CA3026564A1 (en) | 2016-06-06 | 2017-06-06 | Proteasome inhibitors |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA3026564A1 (en) |
WO (1) | WO2017211818A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110357940A (en) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | Ao Puzuo meter synthesising process research |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3592922A (en) * | 1968-07-16 | 1971-07-13 | Chemagro Corp | Process of killing fungi and nematodes with acetylenic ketones |
DE3343531A1 (en) * | 1983-12-01 | 1985-06-13 | Bayer Ag, 5090 Leverkusen | SUBSTITUTED ACETYLENE KETONES |
US7217794B2 (en) * | 2003-04-02 | 2007-05-15 | Daiamed, Inc. | Compounds and methods for treatment of thrombosis |
ES2475945T3 (en) * | 2009-06-26 | 2014-07-11 | Novartis Ag | Imidazolidin-2-1,3-disubstituted derivatives as CYP inhibitors 17 |
CA2769392A1 (en) * | 2009-07-31 | 2011-02-03 | Sandoz Ag | Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method |
-
2017
- 2017-06-06 CA CA3026564A patent/CA3026564A1/en active Pending
- 2017-06-06 WO PCT/EP2017/063699 patent/WO2017211818A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017211818A1 (en) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Socha et al. | Diversity-oriented synthesis of cyclic acyldepsipeptides leads to the discovery of a potent antibacterial agent | |
US20160333054A1 (en) | Small molecule composite surfaces as inhibitors of protein-protein interactions | |
AU2007317045B2 (en) | Michael systems as transglutaminase inhibitors | |
AU2008250254B2 (en) | New cyclic peptide compounds | |
EP1883627A1 (en) | Bir domain binding compounds | |
AU2012235961B2 (en) | Macrocyclic compound and methods for its production | |
WO2017218922A2 (en) | Compositions and methods for the treatment of bacterial infections | |
EP3464321B1 (en) | Proteasome inhibitors | |
EP3458630A1 (en) | Libraries of diverse macrocyclic compounds and methods of making and using the same | |
CA3026564A1 (en) | Proteasome inhibitors | |
JP5634397B2 (en) | Method for producing intermediates for the production of novel macrocyclic compounds such as argylin and its derivatives, which are inhibitors of p27 proteasome degradation, and use of the macrocyclic compounds | |
AU2012328142B2 (en) | Novel dosage form | |
CN110028508B (en) | Antitumor diazo bicyclic apoptosis protein inhibitor | |
WO2016144654A1 (en) | Inhibitors of growth factor activation enzymes | |
EP1169311A1 (en) | Oxazole and thiazole combinatorial libraries | |
ES2265494T3 (en) | PROCEDURE TO PRODUCE TRUNKAMIDA-A COMPOUNDS. | |
WO2020022892A1 (en) | Tubulysin derivatives and methods for preparing the same | |
Zhang | Exploration of novel 2, 4-linked thiazole containing molecules as anti-cancer agents | |
Boys | Tyrosine derivatives and their anti-cancer applications | |
RU2446170C2 (en) | Compounds bound with bir domain of iap | |
Anwar | Synthetic Approaches to Cyclopropyl Peptidomimetics as 20s Proteasome Inhibitors | |
Cain | Synthesis of Biologically Relevant Compounds Harboring Unusual Hydroxamate or Proline Amino Acid Residues | |
Chung | Progress towards the Total Synthesis of Depsipeptide Natural Products: Teixobactin and the Xentrivalpeptide Family | |
US20040033940A1 (en) | Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP | |
White | Synthesis and Site-Specific Functionalizations of Aziridine-2-Carboxylic Acid-Containing Cyclic Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220419 |
|
EEER | Examination request |
Effective date: 20220419 |
|
EEER | Examination request |
Effective date: 20220419 |
|
EEER | Examination request |
Effective date: 20220419 |
|
EEER | Examination request |
Effective date: 20220419 |
|
EEER | Examination request |
Effective date: 20220419 |